<allTrials totalCount="1496" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2026-11-18T16:11:59.517667116Z" version="7" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN44872713" publicIdentifierDateAssigned="2026-11-18T16:11:59.648288Z">
    <isrctn dateAssigned="2026-11-18T16:11:59.648288Z">44872713</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>Transcranial direct current stimulation (tDCS) treatment in adolescent depression</title>
      <scientificTitle>Transcranial direct current stimulation (tDCS) treatment in adolescent depression</scientificTitle>
      <acronym>ADEP</acronym>
      <studyHypothesis>The primary aim of this study is to assess the acceptability of home-based tDCS treatment in adolescents with depression.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Depression can have a major effect on young people’s mood, daily life and wellbeing. Transcranial direct current stimulation (tDCS) is a non-invasive treatment that uses a weak electrical current delivered through a headset to stimulate particular areas of the brain. Studies in adults suggest that tDCS may help reduce symptoms of depression, but less is known about its use at home in adolescents. This study will investigate whether a 10-week course of home-based tDCS is acceptable, feasible and safe for adolescents with depression. It will also explore whether tDCS may be associated with changes in depressive symptoms and brain activity.

Who can participate?
Young people aged 15 to 19 years with a diagnosis of major depressive disorder and mild-to-moderate depressive symptoms, who are under the care of a GP and/or Child and Adolescent Mental Health Services. Participants aged 15 will also need consent from a parent or guardian.

What does the study involve?
Participants will first complete a screening assessment to check whether the study is suitable for them. Those who are eligible will continue their usual treatment and will be randomly allocated, with an equal chance, to receive either active tDCS or sham tDCS. Sham tDCS is designed to feel similar at the start of a session but does not provide ongoing stimulation. Participants will use tDCS device at home after training from the research team. The first session will be supported in person or by video call. Participants will complete 36 sessions over 10 weeks, with each session lasting 30 minutes. During this period, neither participants nor the researchers carrying out the assessments will know which treatment has been allocated. Participants will complete assessments about their mood, wellbeing, treatment experience and possible side effects before, during and after the 10-week treatment period. Some participants may also complete an EEG assessment to measure brain activity. After 10 weeks, participants will be told which treatment they received and will be offered a further 10-week period of active tDCS. A final follow-up assessment will take place eight months after randomisation.

What are the possible benefits and risks of participating?
Participants may or may not experience an improvement in their symptoms. Taking part may help researchers understand whether home-based tDCS could become a useful treatment option for young people with depression. Possible side effects of tDCS are usually mild and temporary. They can include redness, tingling, itching or discomfort under the electrodes, and headache. There is also a small risk of an unusually elevated mood. Participants will be monitored by the research team and will be able to contact them if they have any concerns.

Where is the study run from?
The study is run by the Department of Psychology at the University of East London. Participants will complete the tDCS sessions at home, with remote support from the research team.

When is the study starting and how long is it expected to run for?
September 2026 to December 2028.

Who is funding the study?
The study is funded by Rosetrees Trust and the University of East London through a PhD scholarship.

Who is the main contact?
Amir Mohammad Vafaee Noughabi, u2814815@uel.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="73df7780-fa5b-4469-bfc3-88cb81ec8406">
	  <variable>Treatment acceptability</variable>
	  <method>the Treatment Acceptability Questionnaire (TAQ)</method>
	  <timepoints>week 10, at the end of the double-blind treatment phase</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="09289e96-ae7d-4242-bd1c-aaab8045d645">
	  <variable>Feasibility</variable>
	  <method>recruitment, retention, treatment adherence and discontinuation data from trial and device records</method>
	  <timepoints>week 10, at the end of the double-blind treatment phase</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="0079f3f8-c194-4ea9-98a2-aca0d9dbb2b1">
	  <variable>Safety and tolerability</variable>
	  <method>the tDCS Adverse Events Questionnaire and routine clinical safety monitoring</method>
	  <timepoints>baseline to Month 8 after randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="22b04410-fe7a-46ab-a1a9-729f0254fe04">
	  <variable>Exploratory depressive symptoms-related outcomes</variable>
	  <method>selected validated clinical and self-report measures</method>
	  <timepoints>baseline and  week 10</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="67f958e4-6c75-4e4c-9e73-27fac24ee6f5" approvalStatus="approved" statusDate="2026-07-26T00:00:00.000Z">
	  <committeeName>Yorkshire &amp; The Humber - Sheffield Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>Holland Drive</address>
	    <city>Newcastle upon Tyne</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>NE2 4NQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>25/YH/0198</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN44872713</doi>
      <eudraCTNumber/>
      <irasNumber>352569</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers>
	<secondaryNumber id="9bd1261b-c162-429b-8751-e8e05f6a52ad" numberType="iras" canonicalSecondaryNumber="IRAS352569">352569</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Device feasibility</purpose>
	  <purpose>Health services research</purpose>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2028-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="04570fd9-0098-4829-bc0c-136f2ccde00a">
	  <name>University of East London</name>
	  <address>Department of Psychology and Human Development, Water Lane</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E15 4LZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1.	Adolescents aged 15 to 19 years
2.	Having a diagnosis of major depressive disorder as made by a GP or psychiatrist (e.g., GP services, CAMHS)
3.	Having mild to moderate severity of depressive symptoms as measured by a score of 12 to 34 on the MADRS rating scale
4.	Being medication-free, or taking medication or in psychotherapy, for at least 6 weeks before enrolment
5.	Being under the care of a GP and/or CAMHS
6.	Agreeable for GP to be regularly informed by the research team about participation
7.	Agreeable to have a structured clinical assessment, such as Mini-International Neuropsychiatric Interview Kid (MINI-Kid) for 15-17 years old or MINI for 18-19 years old, for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
8.	Able to provide written, informed consent if 16 years old and above, or able to provide Assent if 15 years old and with parental or guardian written, informed consent</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="15.0">15 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="19.0">19 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1.	Significant suicide risk as measured by answering 'yes' to questions 4, 5 or 6b on the Columbia Suicide Severity Rating Scale (C-SSRS) Screen (Posner et al., 2011)
2.	Primary comorbid psychiatric disorder (e.g., obsessive-compulsive disorder) based on DSM-5 criteria as assessed in MINI-Kid or MINI (Sheehan et al., 1998)
3.	Having a severe depression as measured by a score of above 34 on the MADRS
4.	Current daily use of medications that affect cortical excitability (e.g., benzodiazepines)
5.	History of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), other brain stimulation, or psychosurgery for depression
6.	History of esketamine / ketamine for treatment of depression
7.	Medical disorder that may mimic mood disorder (e.g., hormonal disorder)
8.	Have cognitive impairment
9.	History of a neurological disorder (e.g., structural lesion, epilepsy, seizures)
10.	History of migraines or intractable headaches
11.	Implant in the brain, neurocranial defect, active implantable medical device or any ferromagnetic material in the head</exclusion>
      <recruitmentStart>2026-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-12-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major depressive disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants will continue their usual treatment and will be randomly allocated in a 1:1 ratio to receive either treatment as usual plus active tDCS or treatment as usual plus sham tDCS. During the initial 10-week double-blind phase, participants will use an identical tDCS device at home. Active tDCS will deliver 2 mA stimulation for 30 minutes. Sham tDCS will provide brief stimulation at the beginning and end of each session to mimic initial sensations, without ongoing stimulation. Participants will complete 36 sessions over 10 weeks: five sessions per week for the first three weeks, followed by three sessions per week for seven weeks. They will receive training before using the device and remote support from the research team.

After the Week 10 assessment, treatment allocation will be revealed and all participants will be offered a further 10-week open-label phase of active tDCS. Participants initially assigned to sham tDCS will follow the full 10-week active-treatment schedule; those initially assigned to active tDCS will continue active treatment three times per week. Assessment of clinical depression symptoms and safety will be conducted in Week 0, 1, 4, 10, 20, month 8 after randomisation of each participant.

Randomisation process:
Participants are randomly assigned in a 1:1 ratio to either active tDCS or sham tDCS, using random block sizes and stratification by site through the integrated randomisation system provided by the device provider. During the baseline session at Week 0, participants receive a link to the study app together with an access code. They then download the app and create an account using their email address, password, and study access code. Once the participant account is created within the trial app, the participant is automatically randomised to either the active or sham treatment arm, with a 50% probability of allocation to each group. Block randomisation is used with randomly permuted block sizes of 4 and 6. Randomisation is performed automatically by the trial server, and the allocation is stored in the dedicated trial database.</description>
	<interventionType>Device</interventionType>
	<phase>Not Applicable</phase>
	<drugNames>Flow headset - FL-100 (a Home-based transcranial direct current stimulation [tDCS] device)</drugNames>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>ef4913d5-b3ca-4d04-b0b2-b8bd625b4e2d</funderId>
      <contactId>ff609521-a834-4af2-9578-15c195b11ff5</contactId>
      <contactId>4c2666bc-1dbd-4fa8-a7a1-4f171cfb439b</contactId>
      <sponsorId>4828e518-a7e7-4f8d-89ef-8b9c0ebe15ea</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="ff609521-a834-4af2-9578-15c195b11ff5">
    <title>Mr</title>
    <forename>Amir Mohammad</forename>
    <surname>Vafaee Noughabi</surname>
    <orcid>https://orcid.org/0000-0003-1465-7540</orcid>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychology
University of East London
Water Lane</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>E15 4LZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 7399796725</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">u2814815@uel.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="4c2666bc-1dbd-4fa8-a7a1-4f171cfb439b">
    <title>Dr</title>
    <forename>Cynthia</forename>
    <surname>H.Y. Fu</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychology
University of East London
Water Lane</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>E15 4LZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 20 8223 4119</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.fu@uel.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="4828e518-a7e7-4f8d-89ef-8b9c0ebe15ea">
    <organisation>University of East London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/057jrqr44</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="ef4913d5-b3ca-4d04-b0b2-b8bd625b4e2d">
    <name>Rosetrees Trust</name>
    <fundRef>http://dx.doi.org/10.13039/501100000833</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-18T14:06:02.874637189Z" version="7" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN10952982" publicIdentifierDateAssigned="2026-11-18T14:06:02.998173Z">
    <isrctn dateAssigned="2026-11-18T14:06:02.998173Z">10952982</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>Community Appointment Days compared with standard physiotherapy for people with muscle, bone or joint conditions</title>
      <scientificTitle>Community Appointment Days vs standard physiotherapy for people with a musculoskeletal condition</scientificTitle>
      <acronym>CAD</acronym>
      <studyHypothesis>The aim is to determine whether CADs should be incorporated into the delivery of standard care for people with MSK conditions, and if so, how to optimise implementation for healthcare equity and future sustainability.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
One in three people have a musculoskeletal condition affecting their muscles, bones or joints. This can cause pain, difficulty moving, time off work, and increased chance of conditions like heart disease.

Physiotherapy is standard care which helps, but wait lists are long and there are not many other options.  

Community Appointment Days or ‘CADs’ offer an appointment to help people with their musculoskeletal condition, and other health and social care needs.  

This study wants to see if Community Appointment Days or ‘CADs’ should be a part of musculoskeletal care or not. If the study finds that CADs are helpful, it will also tell us how to make sure as many people can benefit from CAD as possible.  

Who can participate?
Patients 18 years or older, on a musculoskeletal outpatient therapy service wait list at a participating site, who have not attended a CAD before will be eligible.

What does the study involve?
This study compares two ways of providing care. Instead of assigning individual people to different groups, 16 NHS Trusts, across England, Scotland, and Wales will be assigned at random to offer CADs or continue with usual physiotherapy care. Individual consent is for research data collection.  

If a site is assigned to offer a CAD, patients will invited to a CAD at a community venue and offered:  

1. A ‘What Matters to You’ conversation
2. 1:1 therapy assessment  
3. Rehabilitation and advice  
4. Health promotion (blood pressure, glucose, cholesterol tests and BMI)  
5. Access to additional health and social care services  
6. Access to local council, voluntary sector and other support organisations.

Patients will be invited to complete questionnaires before and 3- and 6-months after their first appointment. Some patients and healthcare professionals will be invited to interview/focus groups to share their experience.

What are the possible benefits and risks of participating:
There are no apparent benefits to taking part in this study, but results from this study might help improve healthcare of patients in the future. There is no payment for taking part.  The possible risks of taking part in the study are minimal. It might be difficult to answer some of the questions or could bring up feelings of sadness or distress. Participants do not have to answer any questions that they do not want to answer, and they can decide not to continue with the questionnaire and/or interview at any point.

Where is the study run from?
Queen Mary University of London (UK)

When is the study starting and how long is it expected to run for?
January 2027 to March 2030

Who is funding the study?
National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?
Professor Katie Sheehan k.sheehan@qmul.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="65e8db17-d625-4285-97dc-929ccd2c3d93">
	  <variable>Self-reported overall health</variable>
	  <method>EuroQol Visual Analogue Scale (EQ-VAS)</method>
	  <timepoints>6 months post first appointment</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="da074c08-81db-4a8f-9c27-0a28f50a0706">
	  <variable>Quality of life (generic)</variable>
	  <method>EQ-5D-5L</method>
	  <timepoints>6 months post first appointment</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="4dd2b141-3900-468f-a9c7-1131d2dcde55">
	  <variable>Musculoskeletal health-related quality of life</variable>
	  <method>MSK Health Questionnaire</method>
	  <timepoints>6 months post first appointment</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c55ab7e3-38b2-48e5-b679-78c24a351df0">
	  <variable>Work productivity and activity impairment</variable>
	  <method>Work Productivity and Activity Impairment Questionnaire</method>
	  <timepoints>6 months post first appointment</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="53496290-e772-459e-b46c-150d1753020e">
	  <variable>Depressive symptoms</variable>
	  <method>Patient Health Questionnaire-8</method>
	  <timepoints>6 months post first appointment</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="b23bc66d-31c2-452b-bffd-b3d744c320d6">
	  <variable>Health and care resource use</variable>
	  <method>Health Economic  CRF</method>
	  <timepoints>6 months post first appointment</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="1c9f5fc0-168b-4866-b0bd-6220f27e687e" approvalStatus="approved" statusDate="2026-10-29T00:00:00.000Z">
	  <committeeName>Yorkshire &amp; The Humber - Bradford Leeds Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>NHSBT Newcastle Blood Donor Centre 
Holland Drive</address>
	    <city>Newcastle upon Tyne</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>NE2 4NQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/YH/0195</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10952982</doi>
      <eudraCTNumber/>
      <irasNumber>350919</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 65364</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="5d5f750a-0810-4d75-aa48-613c6125c741" numberType="iras" canonicalSecondaryNumber="IRAS350919">350919</secondaryNumber>
	<secondaryNumber id="3643107b-c57b-4952-bb63-fb745cc8bf6d" numberType="cpms" canonicalSecondaryNumber="CPMS65364">65364</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Health services research</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2029-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Scotland</country>
	<country>Wales</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bed035fb-da6a-4c9c-8e4b-c01cdc9a4198">
	  <name>Airedale NHS Foundation Trust</name>
	  <address>Airedale General Hospital
Skipton Road
Steeton</address>
	  <city>Keighley</city>
	  <state/>
	  <country>England</country>
	  <zip>BD20 6TD</zip>
	  <rtsId>RCF@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="6e65bc76-4b92-439c-90e7-d746e18edd4e">
	  <name>Barking, Havering, and Redbridge University Hospitals NHS Trust</name>
	  <address>King George Hospital
Barley Lane</address>
	  <city>Goodmayes</city>
	  <state/>
	  <country>England</country>
	  <zip>IG3 8YB</zip>
	</trialCentre>
	<trialCentre id="c066693b-fdc9-4f82-9be9-14ea955043fa">
	  <name>Barts Health NHS Trust</name>
	  <address>The Royal London Hospital
80 Newark Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E1 2ES</zip>
	  <rtsId>R1H@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="1137624c-ae15-4ce9-9e2b-7985c5b2a243">
	  <name>Cardiff &amp; Vale University Local Health Board</name>
	  <address>Woodland House
Maes-y-coed Road</address>
	  <city>Cardiff</city>
	  <state/>
	  <country>Wales</country>
	  <zip>CF14 4HH</zip>
	  <rtsId>7A4@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="0218dee9-3557-4f1d-8d50-e7b018952884">
	  <name>East of England Community Health and Care Trust</name>
	  <address>Unit 7-8 Meadow Park Meadow Lane  
St. Ives</address>
	  <city>Cambridgeshire</city>
	  <state/>
	  <country>England</country>
	  <zip>PE27 4LG</zip>
	</trialCentre>
	<trialCentre id="5c8cc973-49f2-4a4f-90c7-2932e11c62b5">
	  <name>Leicestershire Partnership NHS Trust</name>
	  <address>Room 100/110 Pen Lloyd Building
County Hall
Leicester Road</address>
	  <city>Leicester</city>
	  <state/>
	  <country>England</country>
	  <zip>LE3 8RA</zip>
	  <rtsId>RT5@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="755c5d92-036d-4b42-992c-43b6c5fb5ae6">
	  <name>NHS Lothian</name>
	  <address>East Lothian Community Hospital </address>
	  <city>Haddington</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>EH41 3PF </zip>
	</trialCentre>
	<trialCentre id="0b8dbe70-6916-48be-951c-6d1ed62da227">
	  <name>Royal Free London NHS Foundation Trust</name>
	  <address>Royal Free Hospital
Pond Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW3 2QG</zip>
	  <rtsId>RAL@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="e5c1a0c4-c0e3-4ef2-bf9b-eb8fe232dc48">
	  <name>Swansea Bay University Health Board</name>
	  <address>Swansea Bay University Health Board Headquarters </address>
	  <city>Port Talbot </city>
	  <state/>
	  <country>Wales</country>
	  <zip>SA12 7BR </zip>
	</trialCentre>
	<trialCentre id="e3ffbcb8-68fa-4014-8b01-ef7065e10dee">
	  <name>University Hospitals of Morecambe Bay NHS Foundation Trust</name>
	  <address>Royal Lancaster Infirmary  
Ashton Road</address>
	  <city>Lancaster</city>
	  <state/>
	  <country>England</country>
	  <zip>LA1 4RP</zip>
	</trialCentre>
	<trialCentre id="74f48733-84af-4108-bb1b-18ff9c01ec53">
	  <name>York and Scarborough Teaching Hospitals NHS Foundation Trust</name>
	  <address>York Hospital
Wigginton Road</address>
	  <city>York</city>
	  <state/>
	  <country>England</country>
	  <zip>YO31 8HE</zip>
	  <rtsId>RCB@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>Main study: 
Participants will be included if they are: 
1. At least 18 years of age 
2. On a musculoskeletal outpatient therapy service wait list at a participating site 
3. Have not previously attended a Community Appointment Day (CAD)
4. Not currently enrolled in other trials 
5. Provide consent (for sites willing to invite those who lack capacity to consent to their CAD, a personal or nominated consultee will be sought to provide a declaration on their behalf) 
6. At Scottish sites, adults with capacity to consent for themselves  

Process evaluation
Patient Participants: A subset of patient participants purposively sampled to take part in qualitative interviews (up to 1 - hour duration) as part of a process evaluation. This includes patients who: 
1. Attended a CAD
2. Accepted a CAD but did not attend
3. Declined CAD/standard care

Professional participants: 
1. Professionals involved in CAD delivery (managers, commissioners and staff) will be invited to complete a survey. A subset of managers, commissioners or staff employed at one of five CAD delivery sites selected for additional qualitative data collection will be purposefully sampled for the process evaluation
2. Research delivery staff from first eight sites randomised to CAD/standard care for interview to feedback on site set up and delivery</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="120.0">120 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>1452</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>Do not meet the inclusion criteria.</exclusion>
      <recruitmentStart>2027-01-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Patients with a musculoskeletal  condition.</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This will be a multi-centre pragmatic parallel group (allocation ratio 1:1) cluster superiority RCT with an integrated pilot. Sites will be randomly selected to deliver a Community Appointment Day  (CAD) or standard care. Due to the cluster design, all eligible patients at intervention sites will be exposed to the treatment arm regardless of consent status, unless they decline care (e.g., decline CAD in favor of standard care). We will obtain consent from the Clinical Director at each site for the participation of the service in the intervention (cluster guardian). Individual participant consent is therefore sought for data collection only.  

There is a main study, process evaluation, and economic evaluation. 

Main study:  
Potentially eligible participants will be screened from musculoskeletal (MSK) outpatient therapy service wait lists at participating sites by the local clinical research teams.  These individuals will be invited to attend their allocated treatment arm (CAD or standard care, depending on site allocation), be given an explanation of the study, an invitation letter and a Participant Information Sheet (PIS) (either in person, via post, email or telephone). This will be done by a delegated member of the site team. The PIS will be provided when they are invited to attend the treatment day where feasible, otherwise, this will be given to the participant in advance of consent. Consent can be captured in person, electronically, or via telephone. Consent may be obtained in advance or on the day of attendance.   

Intervention:  
Participants will receive the allocated care, CAD or standard of care. Randomisation will occur at cluster level. Sites will be randomized at 1:1 to deliver CAD or standard care. Allocation will be performed centrally via the Pragmatic Clinical Trials Unit at Queen Mary University of London using a computer-generated sequence, stratified by geographic characteristics. Blinding will not be possible due to the nature of the intervention. 

Those allocated to the CAD arm, will attend a  CAD that will include:   
1. ‘What Matters to You’ conversation    
2. 1:1 therapy assessment    
3. Rehabilitation and advice   
4. Health promotion (blood pressure, glucose, cholesterol tests and BMI)   
5. Access to additional health and social care services   
6. Access to local council, voluntary sector, and other support organisations.

Participants will be given a passport to document their ‘What Matters to You’ conversation, what was recommended, and what was completed. There will be time to ask a clinician questions at the end.    

On completion of the CAD, participants may be:  
1. referred to standard care for 1:1 therapy (physiotherapy, but may also be e.g. a hand therapy or an occupational therapy), education, or exercise    
2. referred to other services    
3. referred to GP for follow up from health promotion tests/other concerns    
4. linked to social care/council/voluntary services, and/or    
5. discharged from standard care with/without patient initiated follow up (PIFU).  

Those allocated to the standard care arm, will receive the usual musculoskeletal outpatient therapy as delivered at that site. 

Data collection 
Outcome data will be collected at baseline, and at 3- and 6- months post first appointment regardless of treatment arm. Data will largely be collected electronically via a participant-completed link with direct entry into an electronic capture system. Participants may alternatively request postal data collection (e.g., non-English speaking adults only for outcome measures validated for completion in another language). Telephone data collection will be used to follow up those who have not completed assessments by the link or post.  

They will be required to complete these assessments within 14 (±7) days.  

Sample size 
We aim to recruit 1228 participants across 16 hospital sites in England, Scotland and Wales; 8 sites randomized to deliver CAD and 8 sites to deliver standard care 

Process evaluation:  
The process evaluation will seek to explain the RCT results and inform implementation (if effective) to optimise healthcare equity and future sustainability.  

As part of the process evaluation, quantitative and qualitative data will be collected.  
Quantitative data will include:  
1. Site level data collected from all 16 sites including; geographic location (including site area index of multiple deprivation), number of services within the site, referral pathways (to and from MSK standard care/CAD), number of patients supported by the relevant service/s (patient volume), workforce allocation, transport, and number of CADs held as part of RCT for those randomised to CAD
2. NOMAD questionnaire for managers, commissioners and CAD staff involved in the delivery of CAD who provided consent to contact. They will be sent the NOMAD questionnaire to complete prior to and after CAD delivery
3. Local CAD/standard care policy, guidance and protocols

Qualitative semi-structured interviews/focus groups will be conducted with the following groups: 
1. A subset of patient participants purposively sampled. This includes patients who attended a CAD, accepted a CAD but did not attend and who declined CAD/standard care. Interviews will be one hour long and aim to understand their experience with their care received
2. A subset of service managers, commissioners and staff involved in the delivery of Community Appointment Days (CADs) at one of 5 intervention sites purposively sampled for the process evaluation. The aim is to understand their experience implementing CAD into their service. CAD staff will participate in focus groups up to 90 minutes in duration. Service managers and commissioners from CAD sites will participate in semi-structured interviews up to 60 minutes in duration
3. Research delivery staff from first 8 sites randomised to CAD/standard care. Staff will participate in semi-structured interviews up to 60 minutes in duration. The aim is to understand their experience with study set up and delivery
Interviews will take place by phone, online (via secure videoconference software such as MS TEAMS), or in-person (based on participant preference). 

Sample size: 40 people with MSK conditions,6-8 managers,6-8 commissioners, and 208 staff.

Economic evaluation: 
The economic evaluation will assess whether CAD provides better value for money compared to standard care by comparing costs and quality-adjusted life years (QALYs) over the trial period and modelling long-term outcomes.   

Routinely collected data will be requested for treatment episode, diagnosis and procedure data, healthcare utilisation for participants, (including inpatient, outpatient, critical care and emergency care activity) primary care medicines dispensing, mental health service use, and mortality. Linkage to this data will require use of identifiable data (e.g. NHS number, sex, date of birth, postcode). 

Monthly lists for wait times and volume, referral source, and PIFU volume will be collected in MS Excel. Time horizon will include 6 months pre- and post- CAD date/standard care site green light.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>4f4cf8a3-8eb9-4a25-bda8-4e71f6209e2b</funderId>
      <contactId>5d1e74fb-3e07-4fe7-9353-52d1df56cce4</contactId>
      <contactId>44d1c6a6-0352-4bdb-9281-8417151230bd</contactId>
      <sponsorId>e8975ca0-5afe-43ea-b891-83dc8e8b0bb6</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="5d1e74fb-3e07-4fe7-9353-52d1df56cce4">
    <title>Prof</title>
    <forename>Katie</forename>
    <surname>Sheehan</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bone &amp; Joint Health
Blizard Institute
4 Newark St</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>E1 2AT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 20 7882 2483</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">k.sheehan@qmul.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="44d1c6a6-0352-4bdb-9281-8417151230bd">
    <title>Ms</title>
    <forename>Denise</forename>
    <surname>Bastas</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bone &amp; Joint Health
Blizard Institute
4 Newark St</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>E1 2AT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 20 7882 2483</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cad-bjh@qmul.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="e8975ca0-5afe-43ea-b891-83dc8e8b0bb6">
    <organisation>Queen Mary University of London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/026zzn846</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="4f4cf8a3-8eb9-4a25-bda8-4e71f6209e2b">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-11T08:57:54.009121248Z" version="10" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN60674326" publicIdentifierDateAssigned="2026-11-11T15:11:25.001018Z">
    <isrctn dateAssigned="2026-11-11T15:11:25.001018Z">60674326</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>Using AI to improve recruitment of people with intellectual disabilities and autistic people to research</title>
      <scientificTitle>Using AI to improve recruitment of people with intellectual disabilities and autistic people to research</scientificTitle>
      <acronym/>
      <studyHypothesis>1. Further develop the accessible AI chatbot from the Phase 1 ROK-UK collaboration through co-design with people with intellectual disabilities, autistic people and other key stakeholders
2. Test the safety and feasibility of the AI chatbot through a mixed-methods single-arm feasibility study
3. Use the findings to develop a joint protocol and funding application for a subsequent feasibility RCT examining implementation and other feasibility questions before a future definitive RCT</studyHypothesis>
      <plainEnglishSummary>Background and study aims
People with learning (also called intellectual) disability and autistic people have more health problems and die at least 15 years younger than the rest of the population. To improve their health outcomes, we need to know what treatments work for them. This is usually done through clinical trials. However, we know that up to 90% of clinical trials, where people are allocated to either receive or not receive a treatment by chance (called randomisation) do not include people with learning disability or autism. This means we cannot be sure that treatments tested in people without learning disability or autism, will be appropriate for them.  

Aims of this research: Improve understanding of clinical trial information and support informed decision-making about research participation among people with intellectual disabilities (ID) and autistic people. We aim to do this by developing an artificial intelligence (AI) chatbot to explain research studies in a clear and accessible way and answer people’s questions. 

Who can participate?
Adults with intellectual disability or autistic adults

What does the study involve?
We will speak to people with learning disability, autistic people, their carers and researchers about using an AI chatbot to improve understanding of clinical trials and help them to decide to take part. We will use this information to design and improve the AI chatbot.  We will then test the AI chatbot in a small study. Around 10 people with learning disability and 10 autistic people will use the chatbot to learn about a clinical trial. We will record and analyse data from these interactions. We will also ask participants what they thought about it. We will ask clinical trial experts to use the AI chatbot and give their feedback. We will use what we have learnt to further improve the AI chatbot. 

What are the possible benefits and risks of participating?
No risks to participating in this study except for the person does not enjoying or getting bored by the AI chatbot. No specific benefits except that the person learns about what AI chatbots can do and how to operate them. 

Where is the study run from?
University College London (UK).

When is the study starting and how long is it expected to run for?
July 2026 to June 2028.

Who is funding the study?
National Institute for Health and Care Research (NIHR) (UK). 

Who is the main contact? 
Bhathika Perera, b.perera@ucl.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="e14ada1e-da95-4a97-8c59-e4fb5476a3b4">
	  <variable>Acceptability (≥70% of participants with neurodevelopmental disorders report that the chatbot helped them understand the study)</variable>
	  <method>Likert scale developed by the research team that is suitable for people with intellectual disability</method>
	  <timepoints>the end of using the AI chatbot</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="61930051-c3f2-4756-925d-34a9f4728d75">
	  <variable>Adherence (≥70% of participants complete the chatbot interaction without abandoning the process)</variable>
	  <method>Likert scale developed by the research team that is suitable for people with intellectual disability</method>
	  <timepoints>the end of using the AI chatbot</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="99c07e7b-65ea-4e0d-8b4f-ebf422d3c4f8">
	  <variable>Safety (no serious safeguarding events or misleading advice judged to pose significant risk, and all identified issues can be resolved through iterative refinement)</variable>
	  <method>the records of AI chatbot and interviews with participants</method>
	  <timepoints>the end of using the AI chatbot</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="4c5e02d9-4694-4cc2-8245-c9e294b6c5ce">
	  <variable>Implementation feasibility (the majority (&gt;70%) of research staff indicate that the chatbot could be integrated into recruitment workflows with acceptable operational burden)</variable>
	  <method>Likert scale developed by the research team</method>
	  <timepoints>the end of using the AI chatbot</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="9b07a0da-aaf8-4aa2-abc5-03686a4e24bd" approvalStatus="notYetSubmitted">
	  <committeeName/>
	  <contactDetails>
	    <address/>
	    <city/>
	    <state/>
	    <country/>
	    <zip/>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference/>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN60674326</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NIHR: 516970</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="1ff91ede-9dc9-4b5e-90a1-3e06254f1888" numberType="nihr" canonicalSecondaryNumber="NIHR516970">516970</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>N/A: single arm study</allocation>
	<masking>Open (masking not used)</masking>
	<control>Uncontrolled</control>
	<assignment>Single</assignment>
	<purposes>
	  <purpose>Device feasibility</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2028-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6193678f-332d-41e8-91a8-44efb74325a3">
	  <name>University College London division of psychiatry</name>
	  <address>4th Floor, Wings A and B, Maple House, 149 Tottenham Court Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>W1T 7NF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>true</healthyVolunteersAllowed>
      <inclusion>Adults with intellectual disability and autistic adults, with carers where appropriate who are able to consent to participate in the study. This study registration is for the UK arm of the study as this study is also replicated in South Korea.</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment>20</totalFinalEnrolment>
      <exclusion>1. Any clinical, communication, safeguarding or other circumstance in which the research team judges that participation cannot be conducted safely despite reasonable adjustments
2. Cannot provide informed consent</exclusion>
      <recruitmentStart>2026-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Increase understanding and recruitment of people with intellectual disability or autistic people into clinical trials using an AI chatbot</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Single-arm mixed-methods feasibility study will evaluate use of the AI chatbot and inform iterative refinement.

This feasibility study aims to assess the feasibility of using an AI chatbot to help research participants learn about a study and decide whether to participate. So, the study Intervention is the use the AI chatbot. The duration of the intervention is the duration that each participant uses the AI chatbot. We estimate this to vary from 10 min up to 20 min. We will be monitoring this as part of the feasibility study. There is no follow-up once the participant completes the intervention.</description>
	<interventionType>Device</interventionType>
	<phase>Not Applicable</phase>
	<drugNames>AI chatbot</drugNames>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>a5aed1df-e678-4223-9003-e52853961249</funderId>
      <contactId>2d8ca35e-d339-4907-a625-78c7dc275473</contactId>
      <contactId>4d45caa2-5bdf-413d-9dcb-07168b515585</contactId>
      <sponsorId>50f32064-83a5-4b54-9d39-70f4bbbb1633</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="2d8ca35e-d339-4907-a625-78c7dc275473">
    <title>Dr</title>
    <forename>Bhathika</forename>
    <surname>Perera</surname>
    <orcid>https://orcid.org/0000-0001-9316-9312</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>4th Floor, Wings A and B, Maple House, 149 Tottenham Court Road</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1T 7NF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 20 7504 4186</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.perera@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="4d45caa2-5bdf-413d-9dcb-07168b515585">
    <title>Miss</title>
    <forename>Elle</forename>
    <surname>Kim</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>4th Floor, Wings A and B, Maple House, 149 Tottenham Court Road</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1T 7NF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 20 7504 4186</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ensue.kim.20@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="50f32064-83a5-4b54-9d39-70f4bbbb1633">
    <organisation>University College London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/02jx3x895</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="a5aed1df-e678-4223-9003-e52853961249">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-10T17:09:47.4175482Z" version="13" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN16201377" publicIdentifierDateAssigned="2026-11-10T17:45:16.966895Z">
    <isrctn dateAssigned="2026-11-10T17:45:16.966895Z">16201377</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of reducing appearance related behaviours on body dysmorphic symptoms in university students at risk of body dysmorphic disorder</title>
      <scientificTitle>Effects of reducing appearance related behaviours on body dysmorphic symptoms in university students at risk of body dysmorphic disorder: a randomised controlled trial</scientificTitle>
      <acronym>REFLECT</acronym>
      <studyHypothesis>1. To evaluate the efficacy of the REFLECT intervention compared to an active control by estimating between group effect size difference on body dysmorphic symptoms at 2 weeks. The effect on secondary outcomes, including depressive and anxiety symptoms, will also be examined. 
2. To evaluate feasibility by calculating rates of recruitment and retention to the REFLECT intervention and the control condition
3. To evaluate the acceptability of the REFLECT intervention and the control condition by measuring acceptability and exploring participants experiences of the intervention procedures
4. To evaluate the safety of the REFLECT intervention and the control condition by calculating between group differences in negative effects</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Body dysmorphic disorder (BDD) is a mental health condition in which people worry a great deal about perceived flaws in their appearance and often feel very anxious and ashamed. BDD usually starts when people are teenagers and young adults. Without treatment, it can seriously affect people's lives. People with BDD are more likely to struggle in education and are at higher risk of suicide compared to people without the condition. 
There are effective treatments for BDD, but very few people receive treatment when they need it. We urgently need to develop interventions to help people earlier, before they develop BDD. 
This study aims to test an early intervention strategy for university students who are worried about their appearance, and whose worries are starting to get in the way of their lives. The intervention is based on a treatment already known to work for BDD (namely Cognitive Behavioural Therapy for BDD); it involves a brief 5-minute psycho-educational video, a brief therapeutic technique to practice daily, and daily text reminders. We aim to find out whether the intervention is better at reducing symptoms of BDD compared to an similar control condition.

Who can participate?
People can take part if they: 
1. Aged 18 years or older (there is no upper age limit)
2. Are registered UCL students
3. Have elevated but subclinical symptoms of BDD (this means they are unlikely to have BDD but their symptoms are still impairing)
4. Have not started or changed medication for a mental health condition in the past 6 weeks

What does the study involve?
Participants will first complete some questionnaires which assess whether they are eligible to be take part in the study. Then, they will be randomly assigned to either the intervention or the control condition. The group assigned to the intervention will watch a brief (about 5 minutes) video about the role of appearance related behaviours in maintaining appearance related concerns, are given a brief therapeutic technique to practice daily for 4 weeks and are sent text reminders every day for 4 weeks. Participants assigned to the control condition will also watch a brief video about the role of sleep in appearance anxiety, are given a brief therapeutic technique to practice daily for four weeks and are then sent text reminders every day for 4 weeks, as with the intervention condition. Each week both groups will be asked to complete a brief set of questionnaires. This will allow researchers to assess changes in BDD symptoms, and other mental health symptoms, and whether the participants in the intervention condition report greater improvement in BDD symptoms after 2 weeks compared to the control condition.
We are also interested to see whether the intervention and control are feasible (based on the number of participants recruited and retained in the study), acceptable to participants and are not associated with harmful effects. 

What are the possible benefits and risks of participating?
Participants may benefit from taking part if the intervention helps them feel less BDD symptoms, but, this cannot be guaranteed. Any participant who completes all data collection will be entered into a prize draw for £200. 
Some participants may find part of the intervention or control condition uncomfortable because it involves changing behaviours, which could lead to temporary feelings of anxiety or discomfort. 

Where is the study run from?
University College London (UCL) (UK)

When is the study starting and how long is it expected to run for?
November 2026 to December 2027

Who is funding the study?
UCL Grand Challenge for Mental Health and Wellbeing (UK)

Who is the main contact?
Prof. Georgina Krebs, g.krebs@ucl.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="804ec403-9d62-47e7-8fdd-219ce9719fd9">
	  <variable>Body dysmorphic disorder symptoms</variable>
	  <method>the Body Image Questionnaire (BIQ) (self-report)</method>
	  <timepoints>2 weeks post randomisation</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="6105242c-d3cd-4aa7-9340-0e4b7875a760">
	  <variable>Body dysmorphic disorder symptoms</variable>
	  <method>the Body Image Questionnaire (BIQ) (self-report)</method>
	  <timepoints>4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="83866952-d3d2-4117-aba5-278293e91ab2">
	  <variable>Anxiety symptoms</variable>
	  <method>Generalized Anxiety Disorder-7 (GAD-7) (self-report)</method>
	  <timepoints>2 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="917551e5-897c-4763-aff0-697478581437">
	  <variable>Social anxiety symptoms</variable>
	  <method>the Mini-Social Phobia Inventory (Mini-SPIN) (self-report)</method>
	  <timepoints>2 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="2507c79d-0d94-4e1a-abde-de5ef42212b7">
	  <variable>Eating disorder symptoms</variable>
	  <method>the Eating Disorder Examination-Questionnaire (EDE-Q) (self-report)</method>
	  <timepoints>2 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9161edaf-024b-4f47-b4c4-05d9591ccc65">
	  <variable>Depression symptoms</variable>
	  <method>the Patient Health Questionnaire-8 (PHQ-8) (self-report)</method>
	  <timepoints>2 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="8e2797e6-c933-424e-a414-97831cf34bdb">
	  <variable>Functioning</variable>
	  <method>the Work and Social Adjustment Scale (WSAS) (self-report)</method>
	  <timepoints>2 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9ac95ce6-7a74-483a-93f2-66e9e0f6aa64">
	  <variable>Recruitment into the trial</variable>
	  <method>the number of participants recruited</method>
	  <timepoints>each month</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="08fa3e14-b34d-4b4b-961d-37599768028a">
	  <variable>Retention</variable>
	  <method>the proportion of participants recruited who remain in the trial</method>
	  <timepoints>2 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="508183f9-e217-4e62-9420-2a5b0d4b83ac">
	  <variable>Acceptability of the intervention and control conditions</variable>
	  <method>the Theoretical Framework for Acceptability (TFA) measure (self-report)</method>
	  <timepoints>2 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="fee8629e-7441-414f-8cdc-efed9ca1926b">
	  <variable>Effects of the intervention and control conditions</variable>
	  <method>an open text question and the Negative Effects Questionnaire (self-report)</method>
	  <timepoints>1 week, 2 weeks, 3 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="6a004a22-74dd-4bb1-895b-249249196091">
	  <variable>Appearance related behaviours (intervention condition only)</variable>
	  <method>the self-report assessment of Appearance Related Safety Behaviours</method>
	  <timepoints>1 week, 2 weeks, 3 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="5f553a66-b35e-4b83-bf25-4c9e5e485030">
	  <variable>Sleep hygiene (control condition only)</variable>
	  <method>the Sleep Hygiene Index (self-report)</method>
	  <timepoints>1 week, 2 weeks, 3 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="a9b4dc14-efd7-4b8e-9e20-71a89e76303b" approvalStatus="approved" statusDate="2026-07-07T00:00:00.000Z">
	  <committeeName>UCL Life and Medical Sciences Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>University College London, Gower Street</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>WC1E 6BT</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>3666</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16201377</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers/>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Prevention</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2027-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9c9d1344-acc5-48d8-8fc6-3e1fa28b455d">
	  <name>UCL Department of Clinical, Educational and Health Psychology</name>
	  <address>1-19 Torrington Place</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>WC1H 7HB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Aged 18 years and over (there is no upper age limit)
2. Score between 20 and 39 on the Body Image Questionnaire (BIQ)
3. Be a UCL-registered student</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="110.0">110 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>190</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. BIQ score of less than 20 or 40 and above
2. Not be taking any new or have changed medications for a mental health condition within the previous 6 weeks</exclusion>
      <recruitmentStart>2026-11-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Body dysmorphic symptoms in university students at risk of body dysmorphic disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants will comprise of university students who report elevated but subthreshold body dysmorphic disorder symptoms as assessed by the Body Image Questionnaire (BIQ). Participants will be recruited from a community sample in University College London using physical adverts, digital advertising on platforms including the UCL learning management system - Moodle, and student mailing lists for selected departments within each faculty of the university. 

All participants will be recruited into the trial following a screening study where baseline measures are collected. The design of this screening study was informed by three co-design workshops (n = 8 to 10 UCL students each) held in October and December 2025 and January 2026. These workshops aimed to elicit students’ views on their needs, preferences and potential solutions to improve recruitment and retention to the study and interventions.  

Physical and digital advertisements will include QR codes to enable participants to go directly to the screening study.  
Emails will include the link and digital advert, with both enabling the participant to go to the screening study. 
In the screening study, participants who score between 20-39 on the BIQ will be able to proceed to the participant information sheet for this randomised controlled trial. Branching logic within the REDCap system will enable this process. 

Participants who wish to take part in the study will complete the consent procedure online in the REDCap system to proceed to the trial. All participants will be provided with information about sources of mental health support at UCL, in the NHS and via charities. 

The random allocation of participants to either the intervention or control condition in a one-to-one ratio will be conducted within the REDCap system. The randomisation list will be generated in an Excel document by a researcher independent of the trial personnel and incorporated into the REDCap module by this researcher. This list will not be accessible to the trial personnel, reducing the risk of unblinding. 

The intervention and control allocation and measures will be concealed within REDCap, thereby ensuring the trial personnel are not unblinded to the intervention assignment. 

While participants cannot be blinded to their intervention allocation, the following efforts aim to reduce bias. The intervention and control conditions are similar in terms of credibility scores in a pilot study; credibility scores will be measured following allocation and following delivery of the therapeutic video. Both conditions follow the same structure in terms of activities, timing, form of the therapeutic instruction provided to each participant and the receipt of daily updates for a total of four calendar weeks following baseline. 

Due to the brief nature of the intervention, a procedure for emergency unblinding is not required. 

Both intervention and control conditions will be delivered digitally, whereby participants can access the brief (~5-minute) psychoeducational video and therapeutic instructions via the REDCap system. Both the intervention and control videos are as similar as possible in terms of length, text to read, structure, and style. In both the intervention and control condition, the video is followed by daily text reminders over the following four weeks. 

Intervention condition:
The intervention condition is informed by CBT for body dysmorphic disorder, which has demonstrated efficacy in reducing appearance-related behaviours and body dysmorphic disorder symptoms (Abdalla et al., 2026). The intervention is theory-based in that it draws on the hypothesised active ingredients from CBT for BDD (Patel &amp; Cougle, 2024; Wilhelm et al., 2013). A putative active ingredient is exposure and response prevention (ERP), which involves reducing appearance-related behaviours. These behaviours are a criterion for the diagnosis of BDD and are thought to maintain appearance preoccupation (Patel &amp; Cougle, 2024; Wilhelm et al., 2013). 

The intervention condition is also informed by pilot data and evidence from a randomised controlled trial (Patel &amp; Cougle, 2024). A single-arm pilot study of the intervention was conducted in July 2026, comprising n=29 participants recruited from Prolific. To approximate the age distribution of UCL students, participants were included if aged between 18 and 30 years old. Participants followed the intervention activities of the planned trial: i) viewed a psychoeducational video and therapeutic instructions and ii) were sent daily text reminders for two weeks. 

The intervention will be completed by participants either on a computer, tablet or a mobile phone. Within the REDCap platform, participants will be able to view an approximately five-minute psychoeducational video about the role appearance-related behaviours play in maintaining body dysmorphic disorder symptoms. The video concludes with the therapeutic instructions: 1) to identify appearance-related behaviours and 2) to stop appearance-related behaviours over the following four weeks. After the video, a short four-sentence summary of the key points of the video and the task is shown, and participants are asked to take a screenshot of the summary. Participants then receive daily automated text reminders of the task via REDCap for a total of four calendar weeks. 

Control condition:
The active control condition is based upon evidence that sleep hygiene interventions are a transdiagnostic target for reducing internalising symptoms (Freeman et al., 2017). The active control condition is based on evidence that sleep problems and body dysmorphic disorder symptoms commonly co-occur (Sevilla-Cermeño et al., 2020). Moreover, there is preliminary observational evidence that insomnia has a negative impact on treatment outcomes among individuals with BDD (Sevilla-Cermeño et al., 2020).

This active control condition follows the same structure as the intervention condition. Participants view an approximately five-minute video about how difficulties sleeping can reduce capacity to respond to body dysmorphic disorder symptoms and can intensify distress. The video has a two-step task: 1) to identify areas of sleep hygiene participants can improve, 2) to improve these behaviours. As with the intervention condition, participants will be provided with a short summary of the key points and the task. The schedule of reminders follows the exact same structure as the intervention condition.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study will be stored in a publicly available repository (e.g., GitHub).</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Stored in publicly available repository</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="503fa464-5712-47b6-957f-b281f0b3edf5" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-10-16T00:00:00.000Z" dateUploaded="2026-11-10T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="141f9977-43c0-4758-9eb7-2d007af45d61" originalFilename="50630_Protocol_V1_16Oct2026.pdf" downloadFilename="50630_Protocol_V1_16Oct2026.pdf" version="1" mimeType="application/pdf" length="396870" md5sum="8f448f14d7e736a140c3a38b71c9ceef"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>afa6548c-b39d-43a1-84ba-eb5af9ec817d</funderId>
      <contactId>cc8b2f73-7dec-4728-9ddc-7dec7a438f69</contactId>
      <sponsorId>ae9bfcc6-3eca-43c5-9fd5-3dacb434d327</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/141f9977-43c0-4758-9eb7-2d007af45d61/50630">
	<description>Protocol file</description>
	<name>50630_Protocol_V1_16Oct2026.pdf</name>
	<id>141f9977-43c0-4758-9eb7-2d007af45d61</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>396870</length>
	<md5sum>8f448f14d7e736a140c3a38b71c9ceef</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="cc8b2f73-7dec-4728-9ddc-7dec7a438f69">
    <title>Prof</title>
    <forename>Georgina</forename>
    <surname>Krebs</surname>
    <orcid>https://orcid.org/0000-0002-5353-5645</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>1-19 Torrington Place, University College London</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>WC1E 7HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7679 1897</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.krebs@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="ae9bfcc6-3eca-43c5-9fd5-3dacb434d327">
    <organisation>University College London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/02jx3x895</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="afa6548c-b39d-43a1-84ba-eb5af9ec817d">
    <name>University College London</name>
    <fundRef>http://dx.doi.org/10.13039/501100000765</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-10T10:21:20.446229436Z" version="8" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN46386485" publicIdentifierDateAssigned="2026-11-10T10:21:20.574582Z">
    <isrctn dateAssigned="2026-11-10T10:21:20.574582Z">46386485</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Culturally adapted psychoeducation (CaPE) for African and Caribbean persons with bipolar disorder in the UK</title>
      <scientificTitle>Culturally adapted psychoeducation for African and Caribbean persons with bipolar disorder in the UK: A feasibility study</scientificTitle>
      <acronym/>
      <studyHypothesis>1. To ensure cultural appropriateness of the CaPE manual and study protocol for African and Caribbean persons with bipolar disorder in the UK
2. To test CaPE feasibility and acceptability using a randomised controlled trial design
3. To use ToC and PPIE for sustainable working relationships between persons with bipolar disorder, third-sector organisations and communities
4. To disseminate findings, learn from unanticipated pitfalls and decide on progression to a full trial</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Mental health support in the UK is not always culturally adapted for people from ethnic minority backgrounds who experience mental health challenges, such as bipolar. This study will explore whether offering a Culturally adapted PsychoEducation programme (CaPE) is helpful and appropriate for adults of African and Caribbean heritage living with bipolar in the UK. Participants will either receive the programme alongside their usual routine care, or they will receive their usual care on its own.
This is a feasibility study, which means we are testing out whether the CaPE programme can be delivered successfully and whether people are willing to join and remain in the study. This means that the study may be paused, modified, or stopped earlier than planned. If this happens, participants will be informed about how this impacts them during their participation in the study.
The CaPE programme manual will be developed and improved throughout the study. We will ask participants, therapists, and members of our Research Advisory Group to share their experiences of taking part. Their feedback will help us understand what works well and what could be improved.
Because of this, the manual may change in line with feedback received as the study progresses. This approach helps us make sure the programme reflects what African and Caribbean people living with bipolar disorder say is most helpful and important to them. What we learn will also help us design future support that better meets the needs and preferences of the communities involved.

Who can participate?
We are inviting any person with an African and/or Caribbean ethnic background with a pre-existing diagnosis of any type of bipolar, between the ages of 18 and 60 years, and currently living in the North-West or London. 
You will not be able to take part if you:
•	Are currently experiencing a severe episode of bipolar
•	Have other co-occurring mental health conditions or a severe cognitive impairment that may make it hard to take part in the study
•	Are currently experiencing thoughts of harming yourself or others

What does the study involve?
A Research Support Assistant will meet with you to provide our information sheet and answer any questions that you might have about the study. If you agree to take part, you will be invited to an appointment to sign our study consent form.

You will then be asked to complete some questionnaires to check whether your current mood and mental health meet the study criteria for inclusion. The appointment may last around 30-45 minutes. During the appointment, you will be informed of whether you meet the criteria.
If you meet the study criteria, you will be randomly allocated to one of two possible groups: treatment as usual group (which means to continue with the usual care provided at your General Practice) or the CaPE programme plus treatment as usual group. The CaPE intervention group will be offered 12 weekly online group sessions, each lasting 60 minutes, delivered by trained therapists.
All participants will be asked to complete questionnaires across three time points: at the start of the study, at the end of the intervention (12 weeks) and 3 months after the end of the intervention. 

What are the possible benefits and risks of participating? - We do not expect any significant risks from taking part. While you may not benefit directly, we hope that your participation might help to develop future culturally adapted interventions for bipolar in African and Caribbean communities. All participants from both the CaPE programme group and treatment as usual group will receive vouchers as compensation for their time commitment to the research activities.
Where is the study run from? - Lancashire and South Cumbria NHS Foundation Trust. 

When is the study starting and how long is it expected to run for?
August 2026 to July 2027.

Who is funding the study?
National Institute for Health and Care Research (NIHR) (UK). 

Who is the main contact?
Ellie Taylor, Research Support Assistant, Ellie.Taylor@lscft.nhs.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="06edcd70-c555-4f31-a916-d477a308c9c8">
	  <variable>Recruitment rate</variable>
	  <method>study screening and recruitment logs</method>
	  <timepoints>throughout study</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="3075d20e-010b-49c3-802a-eeb5e429b2e4">
	  <variable>Participant retention</variable>
	  <method>study retention and follow-up records</method>
	  <timepoints>throughout study</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="3d70f699-a094-4443-b704-51da279e8eea">
	  <variable>Session adherence</variable>
	  <method>therapy attendance records</method>
	  <timepoints>throughout intervention period</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="ba468710-2449-44a4-b469-76fa1070830b">
	  <variable>Acceptability of the intervention</variable>
	  <method>service satisfaction scale</method>
	  <timepoints>end of intervention (12 weeks) for participants assigned to intervention arm only</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome>1.	Bipolar symptoms measured using the Brief Bipolar Disorder Symptom Scale (BDSS) at baseline, end of intervention (12 weeks), and 3 months post-intervention
2.	Recovery measured using the Bipolar Recovery Questionnaire at baseline, end of intervention (12 weeks), and 3 months post-intervention
3.	Depression symptoms measured using the Patient Health Questionnaire (PHQ-9) at baseline, end of intervention (12 weeks), and 3 months post-intervention
4.	Medication adherence measured using the Morisky Medication Adherence Scale questionnaire at baseline, end of intervention (12 weeks), and 3 months post-intervention
5.	Health-related quality of life measured using the EQ-5D-3L at baseline, end of intervention (12 weeks), and 3 months post-intervention
6.	Healthcare resource use measured using the Client Service Receipt Inventory (CSR) at baseline, end of intervention (12 weeks), and 3 months post-intervention</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="1ca14dab-9280-47cc-8aae-a2a7c1d09eef" approvalStatus="approved" statusDate="2026-09-28T00:00:00.000Z">
	  <committeeName>North West - Greater Manchester West Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/NW/0217</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46386485</doi>
      <eudraCTNumber/>
      <irasNumber>356103</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 67367, NIHR: 209260</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="39726abd-512c-4873-8bd4-8312a21239d8" numberType="iras" canonicalSecondaryNumber="IRAS356103">356103</secondaryNumber>
	<secondaryNumber id="3fbf8850-4271-48d0-b357-4a668258f48e" numberType="cpms" canonicalSecondaryNumber="CPMS67367">67367</secondaryNumber>
	<secondaryNumber id="88da1805-2673-48fd-85ae-a7ab9ad85ad0" numberType="nihr" canonicalSecondaryNumber="NIHR209260">209260</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Uncontrolled</control>
	<assignment>Single</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2027-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="30481dbd-c1d4-4f85-9d04-2daa70a13a29">
	  <name>Lancashire &amp; South Cumbria NHS Foundation Trust</name>
	  <address>Sceptre Point
Sceptre Way
Bamber Bridge</address>
	  <city>Preston</city>
	  <state/>
	  <country>England</country>
	  <zip>PR5 6AW</zip>
	  <rtsId>RW5@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1.	Adults aged 18–60 years
2.	Self-identified Black British, Black African, Caribbean, or mixed African/Caribbean heritage
3.	A confirmed diagnosis of bipolar I or II, established through existing clinical records and GP or community mental health teams 
4.	Clinically stable enough to participate, as determined through screening measures
5.	Willing and able to engage with mental health services
6.	Resident within the study catchment area (North West England or London)
7.	Able to provide written informed consent and speak English sufficiently to participate in remote group sessions and complete study assessments</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="60.0">60 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>64</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1.	Current severe mood episode, indicated by screening scores above the study thresholds (e.g., YMRS &gt;38 or PHQ-9 &gt;25)
2.	Active suicidality or immediate risk of harm to self or others
3.	Severe cognitive impairment that would prevent meaningful participation in group sessions or completion of study assessments
4.	Comorbid psychiatric conditions that would interfere with participation in a structured psychoeducation programme (e.g., active psychosis, severe personality disorder, or substance dependence requiring urgent treatment)
5.	Any clinical or safeguarding concern identified during screening that, in the judgement of the research team or clinical referrer, would make participation unsafe or inappropriate at that time</exclusion>
      <recruitmentStart>2026-08-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bipolar Disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This study is a feasibility trial. This means we are testing whether it is practical and acceptable to run a larger study of a culturally adapted psychoeducation programme (CaPE) for African and Caribbean people living with bipolar disorder in the UK. We are not testing whether the programme works clinically at this stage. We are looking at whether people are willing to take part, whether the study procedures run smoothly, and whether the CaPE sessions feel useful and acceptable.
Participants will be involved in the study for around six months. Below is a clear description of what will happen, in order.
1. Expression of interest and first contact
People may hear about the study through their GP, mental health team, community organisations, the NIHR Be Part of Research register, or through social media and digital awareness campaigns.
If someone expresses interest, a member of the research team will contact them to explain the study and send the Participant Information Sheet. Everyone will be given time to think about whether they want to take part and to ask questions.
2. Screening and consent
If the person wishes to continue, a screening appointment will be arranged (online or in person). During this appointment, the Research Support Assistant (RSA) will:
- answer any questions 
- check whether the person meets the study’s eligibility criteria 
- confirm their diagnosis of bipolar disorder
- complete short screening questionnaires (PHQ 9 and YMRS)
-take informed consent
How diagnosis will be confirmed:
- If the person is referred through clinical services (e.g., GP, community mental health team), we will use the diagnosis already recorded in their clinical notes.
- If the person is recruited through community organisations or self referral, the RSA will contact their GP or clinical team to confirm their diagnosis.
- If someone is not eligible, the researcher will explain this and signpost them back to their usual care.
3. Baseline assessment
If eligible, the participant will complete a set of questionnaires about their symptoms, well-being, medication, and quality of life. This is called the baseline assessment and helps us understand their starting point before the study begins.
4. Randomisation
After the baseline assessment, participants will be randomly allocated to one of two groups. This is done by an independent statistician, similar to flipping a coin:
- CaPE + usual NHS care OR
- Usual NHS care only
Neither the participant nor the researcher can choose or influence the group they are placed in.
5. Participation in the allocated group
If allocated to CaPE + usual care:
Participants will attend 12 weekly online group sessions, each lasting about 60 minutes. 
Groups will include around six participants and will be led by trained therapists. 
Each session covers a different topic related to bipolar disorder, such as:
- understanding symptoms 
- managing stress 
- recognising early warning signs 
- relapse prevention planning 
Sessions include a short presentation and a group activity or discussion.
If allocated to usual care only:
-Participants will continue with the NHS care they already receive. 
-This may include GP appointments, mental health team support, or medication. 
-They will not attend CaPE sessions during the study but will still be invited to complete the research assessments.
6. Follow up assessments
All participants, regardless of group, will complete the same questionnaires at two further time points:
- At the end of the 12 week intervention period
- Three months after the intervention ends
These can be completed online or with support from the research team.
7. Optional qualitative interview
Some participants will be invited to take part in a one to one interview to discuss their experience of the study. This is optional and will not affect their participation.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study are/will be available upon request. 

Anonymised individual participant data (IPD) from the CaPE feasibility trial will be shared. We will share de identified participant level data including baseline characteristics, treatment allocation, outcome measures (PHQ 9, YMRS, Brief Bipolar Disorder Symptom Scale, Bipolar Recovery Questionnaire, Morisky Medication Adherence Scale, EQ 5D 3L), session adherence, and retention data. No directly identifying information will be shared.

Supporting documents:  
The following documents will be available:
•	Study protocol
•	Statistical analysis plan
•	Data dictionary
•	Blank consent form

When data will become available:  
Anonymised IPD will be available 12 months after publication of the main trial results.

How long data will be available:  
Data will remain available for 5 years after release.

Access criteria:  
Researchers affiliated with recognised academic, clinical, or public health institutions may request access for ethically approved secondary analyses related to bipolar disorder, cultural adaptation of psychological interventions, feasibility methodology, or meta analysis.

Requests must include:
•	A brief analysis proposal
•	Evidence of ethical approval or exemption
•	A data management plan
Access will be granted following review by the Chief Investigator and Sponsor.

Mechanism for data access:  
Requests should be submitted to: Dr Dung Jidong (Chief Investigator)  Email: dung.jidong@manchester.ac.uk
Data will be shared via secure encrypted transfer following approval and completion of a data sharing agreement.

Anonymisation:  
All shared datasets will be fully de identified in accordance with GDPR and NIHR data sharing guidance. Direct identifiers will be removed, and indirect identifiers will be minimised to reduce re identification risk.

Ethical or legal restrictions:  
Data cannot be used for commercial purposes, individual level clinical decision making, or any analysis that risks re identification of participants. Access will only be granted for scientifically and ethically appropriate research.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Available on request</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ea0ce3df-4348-4e40-9b9b-484a54958a1e" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-09-15T00:00:00.000Z" dateUploaded="2026-11-05T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="38214698-7e4f-4e47-8a5e-2c3bcace6f1a" originalFilename="50364 V2_Protocol_CaPE AfroCaribbean bipolar patients_15.09.26.pdf" downloadFilename="50364 V2_Protocol_CaPE AfroCaribbean bipolar patients_15.09.26.pdf" version="2" mimeType="application/pdf" length="619962" md5sum="1b353f7608669ec88292e364dd8729b2"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>c99d3f96-6d3d-4af5-95a6-58d855094586</funderId>
      <contactId>facc6fe8-409c-44c5-b9e4-c632acf97052</contactId>
      <sponsorId>bcc68c92-9038-4882-8845-aac137babcef</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/38214698-7e4f-4e47-8a5e-2c3bcace6f1a/50364">
	<description>Protocol file</description>
	<name>50364 V2_Protocol_CaPE AfroCaribbean bipolar patients_15.09.26.pdf</name>
	<id>38214698-7e4f-4e47-8a5e-2c3bcace6f1a</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>619962</length>
	<md5sum>1b353f7608669ec88292e364dd8729b2</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="facc6fe8-409c-44c5-b9e4-c632acf97052">
    <title>Dr</title>
    <forename>Dung</forename>
    <surname>Jidong</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>The University of Manchester</address>
      <city>Manchester</city>
      <state/>
      <country>United Kingdom</country>
      <zip>M13 9SS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dung.jidong@manchester.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="bcc68c92-9038-4882-8845-aac137babcef">
    <organisation>Lancashire and South Cumbria NHS Foundation Trust</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="c99d3f96-6d3d-4af5-95a6-58d855094586">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-09T13:05:08.786595821Z" version="7" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN12410144" publicIdentifierDateAssigned="2026-11-09T13:05:09.027582Z">
    <isrctn dateAssigned="2026-11-09T13:05:09.027582Z">12410144</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Monitoring blood sugar levels in pregnancy: comparing continuous glucose monitoring with finger-prick testing for gestational diabetes</title>
      <scientificTitle>RandomisEd controlled trial of COntinuous Glucose moNItoring in the management of geStational Diabetes mellitus - a multi-centre randomised controlled trial</scientificTitle>
      <acronym>RECOGNISED</acronym>
      <studyHypothesis>Primary objective
Determine the difference between groups for adverse neonatal outcomes at birth (primary outcome; composite outcome of perinatal death, Neonatal Intensive Care Unit (NICU) admission and Large for Gestational Age (LGA) at 28 days post-natal)

Secondary objectives
1. Determine the difference between groups for other maternal and neonatal clinical, and maternal diabetes behaviour/health-related quality of life outcomes
2. Evaluate the cost-effectiveness of CGM compared with self monitoring of blood glucose (SMBG) testing
3. Assess the acceptability of, and obstacles and facilitators to, CGM use via diabetes treatment satisfaction, maternal quality of life and wellbeing outcomes using qualitative interviews and validated questionnaires to inform future implementation in the wider NHS</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Gestational diabetes mellitus (GDM) is a condition where blood sugar (glucose) levels become too high during pregnancy. Around 1 in 5 pregnant women in the UK develop GDM and this number is increasing each year. GDM is more common in women from minority ethnic backgrounds and those living on lower incomes. It can cause serious problems for mothers and babies, including early birth, babies growing too large or too small, admission to neonatal intensive care, and stillbirth or newborn death. Detecting and managing blood sugar levels reduces these risks and can lower costs to the NHS.

Currently, women with GDM monitor their blood sugar using finger‑prick tests, also called Self Monitoring of Blood Glucose (SMBG), several times a day. This can be painful and inconvenient and only provides limited information, leading to missed chances to reduce complications from GDM. Continuous Glucose Monitoring (CGM) could be a solution. CGM uses a small sensor worn on the arm to measure blood sugar continuously and send readings to a smartphone or reader. It is painless and provides blood sugar level information 24 hours a day that could help healthcare staff and women to lower blood sugar levels and reduce pregnancy complications. 

The RECOGNISED study will recruit pregnant women with GDM from 25 UK maternity centres. Participants will be assigned to one of two groups by randomisation, ensuring both groups are similar. One group will monitor their blood glucose using SMBG (usual care) and the other group will use CGM. RECOGNISED will assess whether monitoring blood glucose using CGM improves outcomes for mothers and babies, reduces NHS costs, and is acceptable to women and healthcare teams, when compared with the current standard of care (SMBG).

Who can participate?
Pregnant women diagnosed with GDM with no other forms of diabetes, and who are being cared for at any hospital participating in the RECOGNISED trial. 

What does the study involve?
Patients who agree to take part will be randomly assigned to monitor their blood glucose using SMBG or CGM until delivery. Participants will be asked to complete questionnaires when they are enrolled, at 34 weeks gestation and at 13 weeks postnatal. Usual care (SMBG) participants will additionally wear a blinded CGM sensor at enrolment and at 34 weeks gestation for two weeks. Some participants will have an additional blood test at 34 weeks gestation to measure HbA1c if that was not previously done as part of their usual care. The research team will also collect routine medical data for the participant (mother) and their baby from randomisation to 13 weeks postnatal. Participants may also take part in an interview to discuss their experiences of the study if they wish to.

What are the possible benefits and risks of participating?
Participants are unlikely to receive any direct benefit from taking part. However, the information collected may help researchers and healthcare professionals better understand different methods of monitoring blood glucose in women with gestational diabetes, which could improve care for future patients.
Participants may experience minor discomfort from using the sensors (e.g. bruising or skin irritation). There is a possibility of sensor malfunction or inaccurate readings, which may require temporary use of finger-prick blood glucose testing instead. Some questionnaires include questions about wellbeing and mental health, which some participants may find upsetting or distressing.

Where is the study run from?
The Bristol Trials Centre, a UK Clinical Research Collaboration registered Clinical Trials Unit, which is part of the University of Bristol’s Medical School, UK.

When is the study starting and how long is it expected to run for?
January 2027 to April 2029. Recruitment to the study is expected to start in January 2027 and will continue for 22 months. Following this, there will be 6 months of follow-up, so the study results will not be expected until the end of 2029.

Who is funding the study?
The National Institute of Health and Social Care Research (NIHR) – Health Technology Assessment Programme (NIHR-HTA), UK.

Who is the main contact?
The central trial team, recognised-study@bristol.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="8bbb4a2e-dbfd-426c-b070-b78066b20621">
	  <variable>A composite primary outcome of: perinatal death (stillbirth/neonatal death ≤28 days of life), NICU admission, and/or large for gestational age baby (LGA, &gt; 90th birth weight centile for gestational age),</variable>
	  <method>data collected from medical notes</method>
	  <timepoints>the delivery of the baby(ies) and at 28 days postnatal for all recruited participants</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="c3b64832-2ce7-4bc0-9a3f-b9d8b9310339">
	  <variable>Glucose control and glucose variability</variable>
	  <method>data collected from CGM devices from randomisation to delivery</method>
	  <timepoints>continuous time points</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="34f5535c-a305-4364-b615-d487c03ca727">
	  <variable>Long term glycaemic control</variable>
	  <method>an HbA1c blood test</method>
	  <timepoints>baseline, 34 weeks gestation and 13 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="a561a925-d1b2-42c9-b5b2-bf2af8278220">
	  <variable>Clinical maternal outcomes (pre-eclampsia, hypertension, weight gain, diabetes treatment, obstetric anal sphincter injury, miscarriage, termination of pregnancy and delivery admission length)</variable>
	  <method>data collected from medical notes</method>
	  <timepoints>baseline, 34 weeks gestation and delivery</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="d66afcc8-1e85-4a16-b026-064e78bb9661">
	  <variable>Clinical neonatal outcomes (components of primary outcome, duration of NICU stay, gestation at delivery, birth mode, neonatal morbidity, birth weight, feeding method, neonatal unit admissions)</variable>
	  <method>data collected from medical notes</method>
	  <timepoints>delivery and 4 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="2cca5d42-46fa-458b-b473-2155ff48515d">
	  <variable>Adverse events for mother and baby</variable>
	  <method>data reported/collected from medical notes</method>
	  <timepoints>from randomisation to 4 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="6d916642-8a92-4300-9c6c-b74d1374a7a1">
	  <variable>Maternal diabetes behaviour</variable>
	  <method>the Summary of Diabetes Self-Care Activities (SDSCA)</method>
	  <timepoints>baseline, 34 weeks gestation and 13 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="977c92d6-6c64-48c9-9ccd-51e9250d95b0">
	  <variable>Glucose monitoring satisfaction</variable>
	  <method>the Glucose Monitoring Experiences (GME-Q)</method>
	  <timepoints>34 weeks gestation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="7af72adc-721e-42ef-93fc-c7710f529980">
	  <variable>Depression</variable>
	  <method>the Patient Health Questionnaire 9-item depression scale (PHQ-9)</method>
	  <timepoints>baseline, 34 weeks gestation and 13 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="ecadd7ae-a411-4616-bf99-c46d1a153738">
	  <variable>Health-related quality of life</variable>
	  <method>the EQ-5D-5L</method>
	  <timepoints>baseline, 34 weeks gestation and 13 weeks postnatal</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="f4858db6-db57-4ede-a4c4-d4e675121ea6">
	  <variable>Maternal and neonatal/infant hospital admissions, outpatient visits and wider NHS resource use</variable>
	  <method>an NHS Resource Use Questionnaire and data collected from medical records</method>
	  <timepoints>from randomisation to 13 weeks postnatal</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="0b8f52a4-8f7c-48d4-9ee3-210cd5d0a3de" approvalStatus="submitted" statusDate="2026-10-26T00:00:00.000Z">
	  <committeeName>North West – Preston  Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/NW/0326</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12410144</doi>
      <eudraCTNumber/>
      <irasNumber>358288</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 68501, NIHR: 170211</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="997cc6a5-b504-4224-930f-aa658735a766" numberType="iras" canonicalSecondaryNumber="IRAS358288">358288</secondaryNumber>
	<secondaryNumber id="499a76f5-2b8c-4c61-8c29-1d170966f3f7" numberType="cpms" canonicalSecondaryNumber="CPMS68501">68501</secondaryNumber>
	<secondaryNumber id="5ea32a51-afb4-4110-9770-7712d82bc555" numberType="nihr" canonicalSecondaryNumber="NIHR170211">170211</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2029-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Wales</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cd2ced56-e6f3-408b-a11d-2ac4919e9c41">
	  <name>St. James's University Hospital</name>
	  <address>Beckett Street</address>
	  <city>Leeds</city>
	  <state/>
	  <country>England</country>
	  <zip>LS9 7TF</zip>
	</trialCentre>
	<trialCentre id="8c84510a-e44e-4025-8aa6-ac8cd0b8208f">
	  <name>Bradford Royal Infirmary</name>
	  <address>Chesnut House
Duckworth Lane</address>
	  <city>Bradford</city>
	  <state/>
	  <country>England</country>
	  <zip>BD9 6RJ</zip>
	  <rtsId>RR842@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="6a46c5e9-2e57-42ba-bda5-b1769eef3431">
	  <name>The Calderdale Royal Hospital</name>
	  <address>Huddersfield Road</address>
	  <city>Halifax</city>
	  <state/>
	  <country>England</country>
	  <zip>HX3 0PW</zip>
	</trialCentre>
	<trialCentre id="92cc9a7e-fcb1-49a8-a5a7-1e75ed86e29c">
	  <name>Liverpool Women's Hospital</name>
	  <address>Crown Street</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L8 7SS</zip>
	</trialCentre>
	<trialCentre id="208c4379-180b-441d-8465-35958b4bb529">
	  <name>Newham University Hospital</name>
	  <address>Glen Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E13 8SL</zip>
	</trialCentre>
	<trialCentre id="661dcb5c-637b-4b05-a329-e15f6bf110fe">
	  <name>Leicester Royal Infirmary</name>
	  <address>Infirmary Square</address>
	  <city>Leicester</city>
	  <state/>
	  <country>England</country>
	  <zip>LE1 5WW</zip>
	  <rtsId>RFR0H@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="36b2fbff-b5f7-4cd6-83d2-9fea6134528f">
	  <name>Royal Derby Hospital</name>
	  <address>Uttoxeter Road</address>
	  <city>Derby</city>
	  <state/>
	  <country>England</country>
	  <zip>DE22 3NE</zip>
	  <rtsId>RTGFG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="65bf2eba-868a-4574-9dad-145389088fc3">
	  <name>Milton Keynes University Hospital</name>
	  <address>Milton Keynes Hospital
Standing Way
Eaglestone</address>
	  <city>Milton Keynes</city>
	  <state/>
	  <country>England</country>
	  <zip>MK6 5LD</zip>
	  <rtsId>RTH83@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f8533210-2c51-449f-b963-a48b17c1b4e2">
	  <name>Norfolk and Norwich University Hospital</name>
	  <address>Colney Lane
Colney</address>
	  <city>Norwich</city>
	  <state/>
	  <country>England</country>
	  <zip>NR4 7UY</zip>
	  <rtsId>RCX09@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="393378a1-9b6e-4aa7-862e-4493a8bbcf35">
	  <name>Southmead Hospital</name>
	  <address>Southmead Road
Westbury-on-trym</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS10 5NB</zip>
	</trialCentre>
	<trialCentre id="a7c8b4a6-91e6-4b58-bfe5-248992b9f9d4">
	  <name>Chelsea and Westminster Hospital</name>
	  <address>Doughty House
369 Fulham Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SW10 9NH</zip>
	</trialCentre>
	<trialCentre id="5e74ac1f-b5be-459a-bfdb-8d6b0bed22c2">
	  <name>West Middlesex University Hospital</name>
	  <address>Twickenham Road</address>
	  <city>Isleworth</city>
	  <state/>
	  <country>England</country>
	  <zip>TW7 6AF</zip>
	  <rtsId>NV182@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="cc2aa9f2-00b6-4dd8-a91e-3ee2099e563f">
	  <name>Royal Berkshire Hospital</name>
	  <address>London Road</address>
	  <city>Reading</city>
	  <state/>
	  <country>England</country>
	  <zip>RG1 5AN</zip>
	  <rtsId>RWX83@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="71be96e7-ab46-42e5-a987-5a996f82d2d9">
	  <name>George Eliot Hospital</name>
	  <address>Lewis House
College Street</address>
	  <city>Nuneaton</city>
	  <state/>
	  <country>England</country>
	  <zip>CV10 7DJ</zip>
	  <rtsId>RKB15@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c8578bb5-29be-4a47-9dd4-8b37240fac62">
	  <name>Jessops Wing</name>
	  <address>Tree Root Walk</address>
	  <city>Sheffield</city>
	  <state/>
	  <country>England</country>
	  <zip>S10 2SF</zip>
	  <rtsId>E6F6R@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="af6de610-a69e-451e-a6cb-efc920cd6474">
	  <name>Kings College Hospital</name>
	  <address>Denmark Hill</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SE5 9RS</zip>
	</trialCentre>
	<trialCentre id="8f2421ed-b1a3-4de1-a1ff-5208a379c672">
	  <name>Stoke Mandeville Hospital</name>
	  <address>Mandeville Road</address>
	  <city>Aylesbury</city>
	  <state/>
	  <country>England</country>
	  <zip>HP21 8AL</zip>
	  <rtsId>RXQ02@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="405008d5-35ec-4a00-b1ac-11066d819ea0">
	  <name>Watford General Hospital</name>
	  <address>Vicarage Road</address>
	  <city>Watford</city>
	  <state/>
	  <country>England</country>
	  <zip>WD18 0HB</zip>
	  <rtsId>RWG02@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="0251fbd5-776d-4e41-872f-293028a1bb89">
	  <name>Gloucestershire Royal Hospital</name>
	  <address>Great Western Road</address>
	  <city>Gloucester</city>
	  <state/>
	  <country>England</country>
	  <zip>GL1 3NN</zip>
	  <rtsId>RTE03@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="25c81258-b9ce-4b78-9267-9309783f7057">
	  <name>Derriford Hospital</name>
	  <address>Derriford Road
Derriford</address>
	  <city>Plymouth</city>
	  <state/>
	  <country>England</country>
	  <zip>PL6 8DH</zip>
	  <rtsId>RH8D2@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="642888e7-d74c-4744-b599-eca52d59092f">
	  <name>Singleton Hospital</name>
	  <address>Sketty Lane
Sketty</address>
	  <city>Swansea</city>
	  <state/>
	  <country>Wales</country>
	  <zip>SA2 8QA</zip>
	  <rtsId>7A3C4@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>Participants may enter the study if ALL of the following apply:
1.	Pregnant, confirmed by presence of foetal heartbeat on either an early viability ultrasound scan performed around 7-8 weeks gestation, or on a dating ultrasound scan at ~12 weeks gestation
2.	Diagnosed with GDM in pregnancy by an oral glucose tolerance test (OGTT) per local diagnostic criteria (NICE or SIGN criteria) or by serial glucose monitoring
3.	Aged 16 years or above
4.	Primiparous or multiparous
5.	Singleton or multiple pregnancy
6.	Up to 31+6 weeks gestation at diagnosis of GDM
7.	Able to give informed consent to participate in the trial</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="16.0">16 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="60.0">60 Years</upperAgeLimit>
      <gender>Female</gender>
      <targetEnrolment>2116</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>Participants may not enter the study (i.e. may not be randomised) if ANY of the following apply:
Women with others forms of diabetes that are not GDM, including type 1 diabetes mellitus, type 2 diabetes mellitus or monogenic diabetes</exclusion>
      <recruitmentStart>2027-01-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Metabolic and endocrine, reproductive health and childbirth</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The RECOGNISED trial is a multi-centre, open-label, parallel group RCT in patients with GDM with internal pilot, embedded qualitative research and a study within a trial (SWAT).  In the RECOGNISED trial, pregnant women with GDM, who have no other forms of diabetes, will be randomised in a 1:1 ratio to monitor their blood glucose using either self monitoring of blood glucose (SMBG; usual care) or CGM until delivery.

The trial will aim to recruit 2116 participants with 1058 participants in each arm from 25 UK sites. An internal pilot will establish whether enough locations can be opened to recruitment and eligible patients can be identified, recruited and will adhere to their allocated treatment over the course of the trial to robustly answer the trial questions. The internal pilot will last for 9 months. If the progression criteria are met, the main trial recruitment will continue and patients from the internal pilot will be included in the final analysis.

Randomisation will take place before 32 weeks of pregnancy. Randomisation will be performed by an authorised member of the local research team using a centralised, computer-generated allocation sequence and secure, web-based randomisation service (https://www.sealedenvelope.com/). Participants will be randomised in a 1:1 ratio to CGM or finger prick SMBG (usual care). Randomisation will be minimised by hospital and stratified by GDM in previous pregnancy/ies (Yes/No).

Participants in the SMBG group will be told to continue monitoring their blood glucose using SMBG. Participants in the CGM group will be shown how to use the CGM system. Participants will complete questionnaires at the baseline visit and the research team will record details about them and their pregnancy. Participants in the SMBG group will additionally have a blinded CGM device fitted which they will wear for 2 weeks.

Participants will be followed up at approximately 34 weeks of pregnancy when they will complete more questionnaires and some participants will have an additional blood test to measure HbA1c if this has not been done as part of usual care. The SMBG group will wear another blinded sensor for two weeks. After the delivery of the baby(ies) and at 28 days postnatal the research team will record details about the delivery and the health of the mother and baby(ies). A final follow up will occur at 13 weeks postnatal, where participants will complete some final questionnaires and the local research team will complete a records review to record clinical and resource use information for the mother and baby(ies).

Patients will also be invited to take part in the embedded qualitative study and can optionally consent to the trial team audio-recording the interviews about their experience. Additionally, a SWAT (Study Within A Trial) will be embedded into the RECOGNISED study. The SWAT will pilot a co-developed AI recruitment video, which can be translated into other languages, at a small number of sites. Participants can optionally consent to interviews to explore the views of participants on the acceptability of the AI video.</description>
	<interventionType>Mixed</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>e9655a8c-1dea-4901-8343-1f571e54f7fc</funderId>
      <contactId>b4a7719d-be27-4c57-80ce-3ef07d36604e</contactId>
      <contactId>2837a90d-cb93-4ea1-91aa-e27a54c84783</contactId>
      <sponsorId>c1883c03-d3be-4208-aa5d-0e428f13735f</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="b4a7719d-be27-4c57-80ce-3ef07d36604e">
    <title>Ms</title>
    <forename>Ellie</forename>
    <surname>Newbury</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bristol Trials Centre, Bristol Medical School, University of Bristol, 1-5 Whiteladies Road, Clifton</address>
      <city>Bristol</city>
      <state/>
      <country>United Kingdom</country>
      <zip>BS8 1NU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)117 455 0629</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">recognised-study@bristol.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="2837a90d-cb93-4ea1-91aa-e27a54c84783">
    <title>Dr</title>
    <forename>Christy</forename>
    <surname>Burden</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Women’s Health Services
Bristol NHS Foundation Trust
Southmead Hospital</address>
      <city>Bristol</city>
      <state/>
      <country>United Kingdom</country>
      <zip>BS10 5NB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">Not provided</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">christy.burden@bristol.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="c1883c03-d3be-4208-aa5d-0e428f13735f">
    <organisation>Bristol NHS Foundation Trust</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/054vvq170</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="e9655a8c-1dea-4901-8343-1f571e54f7fc">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-09T08:17:31.522789782Z" version="12" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN94899823" publicIdentifierDateAssigned="2026-11-09T08:17:31.750563Z">
    <isrctn dateAssigned="2026-11-09T08:17:31.750563Z">94899823</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Using brain wave recordings to detect and monitor delirium in older hospitalised patients</title>
      <scientificTitle>The Delirium Electroencephalography and Phenotyping with Endpoints (DEPEND) study</scientificTitle>
      <acronym>DEPEND</acronym>
      <studyHypothesis>The primary study objective is to develop automated pEEG-based delirium classification and severity measures that detect and grade delirium in older acutely hospitalised patients.

The secondary objective is to examine inter-relationships between these pEEG-derived measures and multi-modal data, including clinical, behavioural, cognitive, blood, and outcome data.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Delirium is a condition of sudden confusion and changes in awareness, affecting around 1 in 4 older patients in hospital at any given time, usually when someone is unwell for another reason. Delirium is very serious. It is linked to longer hospital stays, long-term memory problems, and an increased risk of death. However, it often goes unrecognised by healthcare professionals. At present, doctors and nurses assess delirium using bedside behavioural tests. These can be subjective and hard to interpret, particularly in patients who already have conditions such as dementia.
Electroencephalography (EEG) safely records the brain’s electrical activity through the scalp, and could help detect delirium. However, traditional EEG needs expensive equipment, along with specialists to record and then interpret the signals. In the NHS, EEG is poorly available and there are not enough specialists. Newer portable EEG equipment is much easier to use, and can be fitted at the bedside by non-specialist staff.
This study aims to combine portable EEG with computer analysis to develop an automated, objective bedside measure of delirium. The goal is provide simple numbers describing brain function, similar to how a blood pressure reading gives a simple number describing the circulation.

Who can participate?
The study is open to:
1. Adults aged 65 years and over who are currently in hospital, expected to stay longer than 24 hours, who may or may not have delirium
2. Healthy adults aged 65 years and over living in the community, with no history of delirium, dementia, or other significant neurological or psychiatric conditions.
Delirium can affect a person’s ability to make decisions about taking part. Patients in this situation can still join the study, provided a consultee – usually a relative or close friend who knows them well – agrees that taking part is in keeping with their wishes and feelings.
Participants may also be asked to name an informant: a partner, relative or close friend, ideally someone who has known them for 10 years or more, who can answer some questions about them. Having an informant is helpful but is not required to take part.
People cannot take part if they are on a ventilator, if their confusion is due to alcohol withdrawal, if they have severe scalp skin problems that would prevent an EEG recording, or if they are unable to consent and no consultee is available.

What does the study involve?
Participants take part in up to four types of assessment over about a year.
1. Baseline assessment (during the hospital admission, or at Imperial College London for healthy volunteers): a brain wave recording using a portable EEG headset, computerised memory and thinking tests done on a tablet or computer, a blood sample, and a clinical interview and examination. Hospitalised participants are also asked to wear a smartwatch, and to have a sleep sensor placed under the mattress and a small environmental sensor placed nearby.
2. Repeat assessments (hospitalised participants only): up to five shorter visits, about every 1 to 3 days during the hospital stay, including a portable EEG recording, a clinical examination, and thinking tests.
3. Follow-up assessment (about 6 months after discharge, or after the baseline visit for healthy volunteers): similar to the baseline assessment but without the standard clinical EEG. This can take place at the hospital, at Imperial College London, or at the participant’s home.
4. Remote follow-up (about 12 months after discharge or baseline): by telephone or video call, including a short interview and computerised thinking tests.
The blood samples are taken in the same way as a routine hospital blood test. They are tested for markers of inflammation, of injury to nerve cells, and of neurodegeneration, and for genes involved in brain function, repair and neurodegeneration. 
All assessments are carried out by trained members of the research team. Taking part is entirely voluntary, and it does not affect a participant’s clinical care in any way.

What are the possible benefits and risks of participating?
Participants will not receive any direct medical benefit from taking part. The study may, however, lead to better tools for detecting and monitoring delirium in older hospital patients in future, which could benefit a great many people.
The risks of taking part are minimal. The portable EEG headset is non-invasive and painless, although the electrodes can occasionally feel slightly uncomfortable. The blood sample involves a small needle prick and can cause minor bruising.

Where is the study run from?
The study is sponsored by Imperial College London. It takes place across three Imperial College Healthcare NHS Trust hospitals: Charing Cross Hospital, Hammersmith Hospital, and St Mary’s Hospital, all in London, UK.

When is the study starting and how long is it expected to run for?
September 2026 to April 2030

Who is funding the study?
The National Institute for Health and Care Research (UK)

Who is the main contact?
Dr Gregory Scott, gregory.scott99@imperial.ac.uk</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>Automated portable electroencephalography (pEEG)-based delirium classification (delirium present/absent) and delirium severity score, validated against DSM-5 delirium diagnosis. Severity grading is validated against the Memorial Delirium Assessment Scale (MDAS; range 0–30). This will be measured at baseline, up to five rapid assessments during hospital admission,  and 6-month follow-up.</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Delirium severity measured using Memorial Delirium Assessment Scale (MDAS; range 0–30) correlated with automated portable electroencephalography-based measures; Timepoint(s): Baseline, rapid assessments (days 2–21 of hospital admission), 6-month follow-up
2. Functional outcome measured using Extended Glasgow Outcome Scale (GOSE); Timepoint(s): 6-month follow-up
3. Normalisation of automated portable electroencephalography measures following delirium resolution measured using Automated machine learning analysis of portable electroencephalography signals recorded using the Zeto New Wave headset, compared between acute admission and follow-up; Timepoint(s): Baseline, 6-month follow-up
4. Inter-relationships between electroencephalography measures and multi-modal biomarker and outcome data measured using Correlation of automated portable electroencephalography measures with clinical assessments (Confusion Assessment Method, Montreal Cognitive Assessment), blood biomarkers (inflammatory, neuronal injury, and neurodegeneration markers), wearable sensor data (smartwatch, sleep mat), environmental sensor data, genetic data, and electronic health record data; Timepoint(s): Baseline, rapid assessments (days 2–21 of hospital admission), 6-month follow-up, 12-month follow-up</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="79b2c891-a2c1-4a99-93b6-5737d8fe06aa" approvalStatus="approved" statusDate="2026-02-23T00:00:00.000Z">
	  <committeeName>East of England - Cambridge Central Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/EE/0010</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN94899823</doi>
      <eudraCTNumber/>
      <irasNumber>350632</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 72204, NIHR: 302971, EDGE ref 181924</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="700cbfab-592e-4787-9ac4-3a7d4bdef2bd" numberType="iras" canonicalSecondaryNumber="IRAS350632">350632</secondaryNumber>
	<secondaryNumber id="f78bd76b-dcf9-451a-af24-11bf7c740f3f" numberType="cpms" canonicalSecondaryNumber="CPMS72204">72204</secondaryNumber>
	<secondaryNumber id="bae3055d-b342-46cd-b380-45229ab20c78" numberType="nihr" canonicalSecondaryNumber="NIHR302971">302971</secondaryNumber>
	<secondaryNumber id="3bcf5c70-baf5-4579-a34a-97a79621ad4a" numberType="Protocol number">EDGE ref 181924</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational cohort study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallEndDate>2030-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="07704df4-3c66-4c65-8158-211882f15c4f">
	  <name>Charing Cross Hospital</name>
	  <address>Fulham Palace Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>W6 8RF</zip>
	  <rtsId>RYXC1@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="02d5b284-7707-48e6-a91c-0ce9fa23eb8d">
	  <name>Hammersmith Hospital</name>
	  <address>Du Cane Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>W12 0HS</zip>
	</trialCentre>
	<trialCentre id="890d5c81-de82-47a1-a054-7693a47269d2">
	  <name>St Mary's Hospital</name>
	  <address>Praed Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>W2 1NY</zip>
	</trialCentre>
	<trialCentre id="21bd2c97-4e9c-4b2c-83d3-ae414786c0ad">
	  <name>NIHR Imperial Clinical Research Facility</name>
	  <address>Hammersmith Hospital
Du Cane Rd
Shepherd's Bush</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>W12 0HS</zip>
	  <rtsId>CRF3@2.16.840.1.113883.2.1.3.8.1.2</rtsId>
	</trialCentre>
	<trialCentre id="967d1eca-ae12-4285-8310-dfe5933e8956">
	  <name>UK DRI Care Research &amp; Technology Centre</name>
	  <address>Imperial College London, Sir Michael Uren Hub, 86 Wood Lane</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>W12 0BZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>true</healthyVolunteersAllowed>
      <inclusion>For hospitalised patients (groups a-b):
1. Age &gt;=65 years 
2. Clinically likely to be admitted for &gt;24 hours
3. Able to consent or an available consultee

For healthy participants (group c):
1. Age &gt;=65 years
2. No history of delirium, dementia, or other significant neurological or psychiatric disorder</inclusion>
      <ageRange>Adult</ageRange>
      <gender>All</gender>
      <targetEnrolment>235</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>For all participants (groups a-c):
1. Intubated
2. Delirium due to alcohol withdrawal
3. Unwillingness or anticipated inability to follow all the study procedures
4. Severe scalp skin lesions (e.g., extensive broken skin) that would preclude EEG
5. Lacking capacity to consent and no available consultee
6. Any other medical or psychiatric condition or any treatment which, in the opinion of the investigators, would interfere with the study or compromise patient safety</exclusion>
      <recruitmentStart>2026-09-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2030-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Delirium</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is a longitudinal observational study that involves assessing participants at multiple time points. It does not involve any invasive procedures and it will not interfere with the clinical care of participants.

The study is in people ≥65 years old, also called older people.

The following groups and numbers of participants will be recruited:
1. Older acutely hospitalised patients with possible delirium (n≈135)
2. Older acutely hospitalised patients without possible delirium (n≈70)
3. Healthy older people (n≈30)
Please note that the labels a-c are used hereafter for the three groups of participants.

The study additionally involves:
Informants: someone, e.g. a partner, relative, or close friend, ideally who has known the participant for 10 years or more, who can provide additional information about a participant, which is required for some data collection, and
Consultees: only required if a participant does not have capacity, this is someone who has known the participant well when they had capacity and is willing to be consulted specifically on what the patient’s wishes and feelings would be towards participating in the study.

It may be that the same person, e.g., a participant’s marital partner, has the role of both Informant and Consultee, e.g., if that participant is unable to consent, and therefore a consultee is needed.

The duration of involvement of individual participants is expected to be just over 1 year.

The details of what happens to each participant will depend on which group (a-c) they are in. No study procedures will take place without appropriate consent.

The descriptions of the study procedures are based on our expectations of what will be possible in the ideal case. However, because of the possible impairments present in participants, particularly in hospitalised patients, the full range and form of procedures listed may not always be feasible or appropriate in each individual. Furthermore, some variation in the duration of procedures is expected, on account of clinical factors (e.g., the level of concentration of each participant) and technical factors (e.g., the time taken to attach equipment in an individual).

Relatedly, given the involvement of hospitalised patients, it may be that clinical factors (e.g., the need to undergo clinical procedures, medical deterioration) arise at times when study procedures were planned to take place, or as study procedures are under way. In all such cases, priority will be given to the clinical care of the participant.

The study from a participant’s perspective is summarised in the following list, and then more description is provided afterwards.

 Study overview for hospitalised patients (groups a &amp; b):
×1 Screening
×1 Initial approach
×1 Consent
×1 Baseline assessment (during hospital admission) – involving Clinical interview, Clinical examination, portable EEG (pEEG) + Clinical-grade EEG (subset of participants), Cognitive battery, Blood test, Smartwatch (attached), Sleep mat (deployed), Environmental sensor (deployed)
×≈1-5 Rapid assessment/s (in hospital admission, ≈1-21 days post-baseline) – involving Clinical examination, pEEG, Cognitive battery
Once the participant (groups a &amp; b) has been discharged:
×1 Follow-up assessment (≈6 months post-discharge, at Imperial College Healthcare NHS Trust, Imperial College London, or home) – involving Clinical interview, Clinical examination, pEEG, Cognitive battery, Blood test
×1 Remote follow-up assessment (at home, ≈12 months post-discharge) – involving a Remote clinical interview, Remote cognitive battery
 
Study overview for healthy controls (group c):
×1 Screening
×1 Initial approach
×1 Consent
×1 Baseline assessment (at Imperial College London) – involving Clinical interview, Clinical examination, portable EEG (pEEG) + Clinical-grade EEG, Cognitive battery, Blood test
×1 Follow-up assessment (at Imperial College London, ≈6 months post-baseline) – involving Clinical interview, Clinical examination, portable EEG (pEEG), Cognitive battery, Blood test
×1 Remote follow-up assessment (at home, ≈12 months post-baseline) – involving a Remote clinical interview, Remote cognitive battery
Screening, initial approach, and consenting procedures are described in later, dedicated, sections.

Screening:
Potential hospitalised participants (groups a &amp; b) will be identified by the following two routes:
1. Direct contact between the research team and ICHT clinicians (e.g., doctors, nurses, therapists) who are caring for hospitalised patients admitted at these ICHT hospitals (and would therefore have knowledge of potential participants)
2. Screening of the ICHT electronic health records (EHR) system for patients admitted at these ICHT hospitals by a member of the research team who (1) also has clinical responsibilities (e.g., as part of paid employment or an honorary clinical contract), and (2) could conceivably have clinical responsibility for the care of the hospitalised participants screened (including input as a clinical specialist), but need not be the lead clinician for these participants, and (3) already has clinical access to the EHR system as part of these responsibilities.

Potential healthy participants (group c) will be recruited from the following four routes:
1. Existing healthy volunteer databases held at Imperial College London (ICL), 
2. By inviting friends or family members of patient participants, including their informants or consultees,
3. Existing healthy volunteer databases held at the NIHR Imperial Clinical Research Facility (ICRF), and
4. Existing healthy volunteer databases held at Join Dementia Research (JDR).

Initial approach and consent:
The approach and consent procedures are described in detail in A29 and B7; the following is a summary.
All participants are assumed to have the capacity to consent unless it is evident that they have difficulties with understanding information and making choices. The capacity of a patient to consent to research participation will be initially assessed during screening.

If this assessment, or the impression during the initial approach to a patient, concludes that the patient does not have capacity, the clinical care team will identify a suitable consultee, i.e., a person who has known the patient well when they had capacity and is willing to be consulted on what the patient’s wishes and feelings would be towards participating in the project.

If no consultee can be identified, the patient will not be involved in the research.

Assessments:
This section, to be read in conjunction with summaries above, describes the details of assessments from the perspective of participants, including the types and locations of assessments, and what procedures will take place.

The four types of assessment are:

Baseline assessment (groups a-c):
A more detailed assessment carried out once in all participants, and similar for all participants (but not identical, e.g., since some aspects do not apply to healthy controls)

Rapid assessment/s (groups a &amp; b only):
A shorter assessment carried out up to about five times, in hospitalised participants only, intended to be done periodically (every 1-3 days) during their stay.

Follow-up assessment (groups a-c):
A detailed assessment, similar to the baseline assessment, carried out once in all participants, and similar for all participants (but not identical)

Remote follow-up assessment (groups a-c):
A shorter assessment carried out once remotely (e.g., over the telephone from the participant’s home or usual place of residence) in all participants, and similar for all participants (but not identical).

Locations:
There are several types of location for assessments:
In hospital admission (groups a-b only)
This location applies to Baseline and Rapid assessments. The assessments at this location will take place in the hospital where the patient is admitted, i.e., a hospital ward within Imperial College Healthcare NHS Trust (ICHT).

The research team will ‘come to the patient’ and carry out all the research procedures. The research team will work with the clinical care team to ensure that the research procedures do not interfere with the patient’s care. The participant will be in their usual hospital bed. Baseline assessments at this location additionally involve attaching a smartwatch sensor, deploying a sleep mat under the bed mattress, and placing an environmental sensor nearby, but these activities require minimal or no action from the participant.

Imperial College London (groups a-c):
This location applies to Baseline (for group c) and Follow-up assessments (groups a-c). The assessment will take place at the UK Dementia Research Institute Care Research &amp; Technology Centre (CR&amp;T), 9th Floor, Sir Michael Uren Hub, Imperial College London, White City Campus, 86 Wood Lane, London, W12 0BZ. Participants and any carer will travel to/from this site. Participants will be reimbursed for their travel costs. They will be greeted upon arrival at reception by a member of the research team. A member of the research team will be with the participant throughout the visit/assessment. The research procedures will take place with the participant sitting in a private room at the CR&amp;T.

Imperial College Healthcare NHS Trust (groups a-b only):
This location applies to Follow-up assessments, as an alternative to an assessment at Imperial College London (above), if (1) the participant is being seen in a clinic, which the clinical team may have referred to for clinical reasons, and (2) this is both convenient for the participant and possible for the research team, in terms of practicalities, and suitability for the timing of the assessment ~6 months post-discharge from hospital. In this case, the research team will have confirmed in advance that there is time and a suitable place at the site, e.g. in or nearby the clinic, to complete the assessment at the same hospital site as the participant’s clinic appointment. A member of the research team will be with the participant throughout the visit/assessment. The research procedures will take place with the participant sitting in a private room.

At home (groups a-b only):
Given some of the participants in groups a &amp; b may not be able to leave their homes on account of their medical problems, a member of the research team may be able to visit the participant at home, i.e., their place of residence, which could include a care home.

In the scenario where participants are living not at home but in, e.g., supported accommodation, care homes or nursing homes, no such residence would be considered a research site (i.e., no active staff involvement or record access), but rather the “place of residence” of the participant. In these cases, the research team will obtain local permission from the manager of the site (e.g. care home manager) in order to conduct the follow up visit on the premises. The sponsor’s insurance covers researcher activities in these non-NHS premises.

Remote follow-up assessment at home (groups a-c):
This location applies to Follow-up assessments. The assessment will be carried out remotely by the research team, i.e., over the telephone, Teams, or Zoom, whichever the participant or consultee prefers. The participant will be based in their home, i.e., their place of residence, which could include a care home.

For the Follow-up and Remote assessments, arrangements will be made over the telephone or email with participants, their next-of-kin, or their consultees, and they will be reminded in advance of future assessments, by telephone, and optionally email.

Procedures:
From a participant’s perspective, the following procedures will take place as part of the assessments. These procedures often involve collection of multiple items of data but are here described in terms of a participant’s experience of the procedures. The number of procedures is shown in the summary above.

Clinical interview:
The participant will answer a range of questions from a research team member, including about their medical history, medications, social circumstances, and current problems. This will be similar to a consultation with a doctor. Some questions are from standardised questionnaires. The informant will also be asked questions, which complement
the information provided by the participant, e.g. in cases where the participant is not able to provide details because of memory impairment, and there will be some standardised questionnaires specifically meant for informants to provide a perspective on the participant.

A version of this interview will be performed remotely for the final (remote) assessment.

Clinical examination:
The participant will be examined by a research team member from a neurological perspective using standardised behavioural tests. This will include observation of the participant at rest, asking the participant questions (such as their name and address, the current date and location), asking the participant to follow commands, (such as opening the
eyes), and asking them to perform some tests, such as repeating back a sequence of numbers. For some hospitalised participants who have a low level of consciousness, this examination may require administering a brief painful stimulus like that used in standard clinical care to assess level of consciousness, e.g., a sternal rub (pressure over the breastbone); this is a standard procedure to grade consciousness in patients who are not already responsive and who do not respond to voice.

Portable EEG (pEEG):
The participant will have a portable electroencephalogram (pEEG), attached and recorded by a research team member. EEG is an entirely non-invasive recording technique, monitoring the brain’s electrical activity from the scalp. pEEG involves the placement of ~20 ‘dry’ electrodes within a cap placed on the scalp. This form of EEG is simpler and requires less preparation time compared to clinical-grade EEG (below). We will be using pEEG equipment that is specialised for research purposes. The participant is not required to do anything for us to record an EEG, but they may be asked, e.g., to open/close their eyes for periods. There are no side effects from a pEEG. The electrodes and cap are not painful. They may occasionally feel slightly uncomfortable or leave a temporary red mark on the skin. Localised allergic reactions to any material on the skin are possible, but this is thought to be extremely unlikely.

In a subset of participants, a clinical-grade EEG will be performed near the time of pEEG, and once only, to allow direct comparison of signal quality. The participant is not required to do anything for us to record a clinical-grade EEG, but they may be asked, e.g., to open/close their eyes for periods. Clinical-grade EEG is the form of EEG already used in routine clinical care. It is similar to pEEG, but uses about 20 ‘wet’ electrodes, attached individually to the scalp using a gel/paste. The set-up time is therefore longer. Two electrodes are attached to the shoulders to provide a simultaneous heart tracing. The electrodes are not painful. The material used to attach electrodes can leave some minor residue on the skin or hair afterwards which can be wiped away with wet cotton wool, and can leave a sticky feeling that comes out during normal washing.

Cognitive battery:
The participant will have cognitive tests, i.e., assessments of thinking, memory, etc., administered using a computer tablet (e.g. an iPad) or their own computer. This is carried out using an online platform called Cognitron, that involves a battery of up to 12 tests (including object memory, digit span, and verbal analogies). This is similar to playing simple computer games or puzzles. For in-person assessments (Baseline, Rapid, Follow-up), this will be supervised by a research team member. For remote assessments, this can be done by the participant from home using their own device. They will be sent a link to a website via their email address. If they do not have a device to complete the remote assessments, they will not have to complete them.

The cognitive tasks used have been previously used extensively in different research settings including in people with a range of medical and psychiatric problems. The cognitive tasks that the participant completes will vary according to their level of impairment, from no tasks at all (e.g. in those who have a low level of consciousness), to a range of tasks that tests different aspects of cognition. Participants will be able to take breaks in between tasks if needed.

Blood tests:
The participant will have a blood test, performed by a research team member. The blood will be taken in the same way as a routine blood test. The blood sample (up to about 25ml or two tablespoons of venous blood) will be used to test for inflammatory, neuronal injury, and neurodegenerative blood markers. We will also use this sample to look for genes involved in brain function, repair, and neurodegeneration. The blood samples will be stored and then processed in large batches. The technology for analysing the blood tests is called a “panel”, which measures a large number (&gt;100) of different molecules at the same time to provide a detailed characterisation.

Smart watch, sleep mat, and environmental sensor:
For patients in hospital (groups a-b), the participant will be given a “smart watch”, attached by the research team, to wear continuously for up to thirty days during their hospital stay. This is like a normal watch, but it additionally continuously captures information about movement, heart rate, and some other physiological information. The research team will retrieve the data from the watch about once a week, which does not require any action from the participant. The watch will be removed before hospital discharge.

The research team will also place an environmental sensor near the patient but out of the way of any clinical equipment or belongings. This is like the device a parent might use to monitor their baby’s bedroom environment. This sensor records the room temperature and light levels. It is thought that the hospital environment can sometimes contribute to the development of delirium. This sensor could therefore provide some useful additional information about this possibility as well as information about the range of environmental conditions in all patients studied.

In addition, the research team will place a pressure sensor under the hospital bed mattress. This 'sleep mat' continuously senses a participant’s movement and aspects of their heart rate and breathing rate when they are in bed.

It also contains a microphone to identify snoring, but no sound recordings are saved. Some people use these devices to track their health at home.

The research team will retrieve the devices when the patient is discharged or after thirty days of hospital stay, whichever is sooner, which does not require any action from the participant.

Sleep mat installation at home:
Additionally, following discharge, in addition to use of the sleep mat in hospital, for patients in hospital (groups a-b), and with the participant’s (or consultee’s) permission, if the participant has a home internet connection, the same ‘sleep mat’ device will be installed under the participant’s own mattress in their home, i.e., place of residence, which
could include a care home. This is to gather the same information in the home setting, to compare it with the data from hospital and the other data collected. It plugs into the mains electricity but uses very little power. It connects to the internet either via a cellular data hub or via existing WiFi.

The device is easy to install, and it will either be (1) posted to the participant to self-install, or with the help of someone else in the residence, or (2) installed by the research team, with the appropriate permission. Installation usually takes up to half an hour. Having the device in the home does not require the participant to do anything. In the unlikely event that the device stops working (e.g., data is no longer being collected, something we will be able to detect remotely), we will contact the participant about this and arrange to fix or replace it. The research team will also arrange collection of the sleep mat at the time of the 6 month follow-up assessment, either asking the participant to bring it to the appointment or collecting it from the participant’s place of residence.

End of study:
After the 12-month remote follow-up assessment, participation in the study will end for all participants (groups a-c).</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>Anonymised multi-modal data generated by this study, including EEG recordings, clinical, cognitive, and outcome data, will be made available via a publicly accessible data repository at study completion, subject to applicable ethical and data governance requirements. Analysis code will be made openly available (e.g., via GitHub).</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Stored in publicly available repository</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>02db7044-5c40-48a8-bde8-ca72acc870ac</funderId>
      <contactId>a0f1d2f9-ca46-4e55-ac7e-ca505f4faad1</contactId>
      <contactId>1404b4a5-060f-45ec-bdd9-8a146c7fd834</contactId>
      <sponsorId>73c48244-bfa0-4a4c-92d9-415e952c0fb8</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="a0f1d2f9-ca46-4e55-ac7e-ca505f4faad1">
    <title>Dr</title>
    <forename>Gregory</forename>
    <surname>Scott</surname>
    <orcid>https://orcid.org/0000-0001-8063-5871</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>9th Floor, The Sir Michael Uren Hub, Imperial College London, 86 Wood Lane</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W12 0BZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)2075947875</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gregory.scott99@imperial.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="1404b4a5-060f-45ec-bdd9-8a146c7fd834">
    <title>Dr</title>
    <forename>Abdullah</forename>
    <surname>Virk</surname>
    <orcid>https://orcid.org/0009-0008-6344-9506</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>9th Floor, The Sir Michael Uren Hub, Imperial College London, 86 Wood Lane</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W12 0BZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)7308395095</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.virk@imperial.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="73c48244-bfa0-4a4c-92d9-415e952c0fb8">
    <organisation>Imperial College Healthcare NHS Trust</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/056ffv270</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="02db7044-5c40-48a8-bde8-ca72acc870ac">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-05T08:54:35.29409371Z" version="9" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN15392005" publicIdentifierDateAssigned="2026-11-05T08:54:35.512158Z">
    <isrctn dateAssigned="2026-11-05T08:54:35.512158Z">15392005</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Holistic health and care support for people experiencing homelessness in temporary accommodations (REACH)</title>
      <scientificTitle>Strengths-based, low caseload approach to integrated health, housing and practical support for people experiencing homelessness with multiple complex needs in temporary accommodations: a multi-centre, open-label, cluster randomised controlled trial with embedded economic and qualitative process evaluation</scientificTitle>
      <acronym>REACH</acronym>
      <studyHypothesis>Primary Objective
To reduce the number of Emergency Department (ED) attendances for all causes over 12 months following baseline assessment in the intervention arm compared to usual care arm

Secondary Objectives
1. Improve health and wellbeing (e.g. mortality, physical health, mental health, quality of life EQ-5D-5L, substance including alcohol use)
2. Evaluate impact on healthcare resource use (e.g. ED presentation for overdose, mental health conditions; ambulance call outs, hospitalisation, use of mental health, substance use treatment, harm reduction and nominated pharmacy services) 
3. Improve social outcomes (e.g. employment, housing, criminal justice encounters)
4. Evaluate cost-effectiveness of REACH 
5. To evaluate implementation process, understand mechanisms of impact and acceptability of REACH to study participants, REACH care team, temporary accommodation staff and wider stakeholders (process evaluation)</studyHypothesis>
      <plainEnglishSummary>Background and study aims 
People who experience homelessness (PEH) suffer from poor physical and mental health. Many die in their early 40s as they do not receive timely help and treatment for their health and care needs. Most of these deaths can be prevented. Temporary accommodations (e.g. hostels) are often the first housing support for PEH. Despite housing some of the sickest citizens of society, there is no national guidance to tell us how health and care should be provided to temporary accommodation residents. Many residents with complex health and care issues struggle to move on as they are unable to receive the support they need. One person described to us that they spent 14 years in a hostel, mostly stuck in their room with mental health problems and no support. Many also return to the streets as they lack opportunities, and experience loneliness and boredom. 

This study will test a 'joined-up' way of delivering care in hostels. This has been called 'Reach, Engage and Recovery' (REACH) and it will involve mental health practitioners (e.g. mental health nurses) and care navigators providing support to temporary accommodation residents. 

Who can participate? 
Adults aged 18 or older who are a resident of a temporary accommodation, with one or more of the following: mental health problem, substance (includes alcohol) use, history of criminal justice encounter and/or equal to or longer than 6 months in one stay or repeat stay in temporary accommodations.

What does the study involve? 
The care team will have a low number of people to look after, which allows them to offer focused support for people who have high health and care needs. The care team will check, treat and refer people to improve their physical and mental health, wellbeing, practical skills for recovery and employment. This study will take place across  temporary accommodations for PEH based in London, Midlands, North of England and Scotland. Temporary accommodations will be divided into two groups, with residents of one group receiving the REACH care and the other group receiving the care as usual. 

The REACH group will receive support from the care team for 12 months, allowing rapport building over this period of contact and opportunities to establish positive changes. The REACH team will check residents' physical, mental health, housing, practical needs and provide trauma-informed (being aware of life situations) care. They will work with local community organisations to support skills (e.g. volunteering, gardening, mentoring, arts/crafts, employment training), address loneliness and promote wellbeing. They will focus on individual's strengths and goals as they support long-term recovery. Data will be collected to evaluate whether REACH reduces Emergency Department (A&amp;E) visits, repeat homelessness, offending, resident deaths and improves housing uptake, quality of life and employment. Views will be obtained from PEH and service providers' views about REACH and the study will find out if it saves money for the health and care system. 

The study team have partnered with key national providers of hostels, health services and charities to better understand what is needed to roll out REACH across the UK. Study partners HomelessLink and Pathway will share the study findings with PEH, Government Departments and wider stakeholders. They plan to publish results in scientific journals and present the  findings in forms that are accessible to PEH. 

REACH was co-designed through discussions with members of a lived experience advisory group on homelessness at King's College London. They will remain advisors on the study. The study team also spoke to residents of temporary accommodations as well as frontline staff and managers. Participants recommended that REACH should focus on people who are most likely to fall through the gaps. One of the study's co-applicants has lived experience of homelessness.

What are the possible benefits and risks of participating? 
This study could help improve care for people who are experiencing homelessness. Participants in the intervention arm may receive additional support throughout the study. There are no anticipated risks or disadvantages of taking part in the study. Some questions may be upsetting but these are similar to questions in normal care.

Where is the study run from?  
King's College London, UK.

When is the study starting and how long is it expected to run for? 
March 2027 to October 2029.

Who is funding the study? 
The National Institute for Health and Care Research (NIHR), UK.

Who is the main contact?
Prf Vibhu Paudyal, vibhu.paudyal@kcl.ac.uk.</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="a67d8f9f-f76d-4546-aae0-9412d44e48e8">
	  <variable>Number of ED attendances for all causes during the 12 months following the baseline assessment</variable>
	  <method>data collected from NHS records held centrally in England and Scotland</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="cd4404e8-dd98-4b39-a199-3e223524795a">
	  <variable>All-cause mortality</variable>
	  <method>NHS and temporary accommodation records to count the number of deaths in the 12 months follow up period- data collected</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="27ca2082-b4f4-42b8-859f-273d1fb5c96e">
	  <variable>Quality of life</variable>
	  <method>EQ-5D-5L- data collected via participant self reports</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="5f22e49b-131d-400f-8e1e-6ae1fbf3f505">
	  <variable>Physical health problems or diagnosis</variable>
	  <method>NHS records and participant self reports to count long term physical health problems</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="fac5ae30-af3a-4644-93d6-702dfec7c3a1">
	  <variable>Mental health problems or diagnosis</variable>
	  <method>NHS and participant self reports to count long term mental health problems</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="640b01a0-591c-437b-8401-3bd48001ae85">
	  <variable>Current substance use</variable>
	  <method>ASSIST-LITE scores from participant self reports</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="26bc23cd-3a0f-4e00-bad9-896a2f183508">
	  <variable>Prescribed treatment for diagnosed substance use disorder</variable>
	  <method>whether currently on treatment: data collected via participant self reports, substance use treatment services and temporary accommodation records</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9cada968-e6dc-4761-8d45-24699cf1a7a0">
	  <variable>Self-efficacy</variable>
	  <method>the PROMIS General Self-Efficacy Scale via participant self reports</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="0990fc10-a74b-4656-93fd-a2fafa47d39a">
	  <variable>Capability and wellbeing</variable>
	  <method>the ICEpop CAPability measure for Adults (ICECAP-A) via participant self reports</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c034221e-78c8-4b67-a25d-f1c8819d4812">
	  <variable>Healthcare and resource use over 12 months, accounting for person-years of follow-up, e.g. the number of ED presentations for substance use, number of ambulance call outs,</variable>
	  <method>NHS records, ambulance records, participant self reports and temporary accommodation records</method>
	  <timepoints>12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="044b3670-fba1-4927-a2a5-207c53bd9af1">
	  <variable>Social Outcomes (e.g. current housing status, criminal justice encounters, employment status)</variable>
	  <method>questionnaire completion with participants/temporary accommodation staff</method>
	  <timepoints>3, 6 and 12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9f24df3f-9553-4046-aae7-a0aefe639513">
	  <variable>Economic evaluation outcomes [E.g. Cost-effectiveness – incremental cost per QALY gained]</variable>
	  <method>economic evaluation</method>
	  <timepoints>12 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c46670df-8d61-420c-87fc-c7c2ffacec16">
	  <variable>Exploratory outcomes (e.g. satisfaction with mental and physical health care, and substance use treatment)</variable>
	  <method>questionnaire completion</method>
	  <timepoints>12 months</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="56aa82d6-05e1-4a90-aa9d-491711430074" approvalStatus="submitted" statusDate="2026-10-15T00:00:00.000Z">
	  <committeeName>Wales REC 1</committeeName>
	  <contactDetails>
	    <address>Health and Care Research Wales, Floor 4, Crown Building</address>
	    <city>Cardiff</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>CF10 3NQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/WA/0317</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15392005</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 68171, NIHR: 174677</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="4f64b7f7-658a-4671-add6-0aa396ed465c" numberType="cpms" canonicalSecondaryNumber="CPMS68171">68171</secondaryNumber>
	<secondaryNumber id="6fec4d14-4a15-4095-8f7e-ad6a6cc0a87e" numberType="nihr" canonicalSecondaryNumber="NIHR174677">174677</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Health services research</purpose>
	  <purpose>Supportive care</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2029-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Scotland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="04ad0090-a3e3-48af-aefc-f30da8355555">
	  <name>South London and Maudsley NHS Foundation Trust</name>
	  <address>Bethlem Royal Hospital
Monks Orchard Road</address>
	  <city>Beckenham</city>
	  <state/>
	  <country>England</country>
	  <zip>BR3 3BX</zip>
	  <rtsId>RV5@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="23736134-3ea8-4d8a-a4f5-50cb1c799bce">
	  <name>Oxleas NHS Foundation Trust</name>
	  <address>Pinewood House
Pinewood PLACE</address>
	  <city>Dartford</city>
	  <state/>
	  <country>England</country>
	  <zip>DA2 7WG</zip>
	  <rtsId>RPG@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="55dcee17-d7a1-4589-a557-721d599783d3">
	  <name>Birmingham and Solihull Mental Health NHS Foundation Trust</name>
	  <address>The Uffculme Centre
52 Queensbridge Road
Moseley</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B13 8QY</zip>
	  <rtsId>RXT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c1b21257-2dfe-41b7-9c09-bfa393b9bb91">
	  <name>North London NHS Foundation Trust</name>
	  <address>4th Floor, East Wing
St. Pancras Hospital
4 St. Pancras Way</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 0PE</zip>
	  <rtsId>G6V2S@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="968635bc-2d1c-4ab8-8a86-8e0345ba7a57">
	  <name>East London NHS Foundation Trust</name>
	  <address>Robert Dolan House
9 Alie Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>E1 8DE</zip>
	  <rtsId>RWK@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f49506d8-e907-4855-bd69-575acc5788cb">
	  <name>NHS Lanarkshire</name>
	  <address>Kirklands, Fallside Road</address>
	  <city>Bothwell</city>
	  <state/>
	  <country>Scotland</country>
	  <zip>G71 8BB</zip>
	  <rtsId>SL999@2.16.840.1.113883.2.1.3.8.2.16.1</rtsId>
	</trialCentre>
	<trialCentre id="a938e2be-0af1-497f-b528-0bd00f9dac32">
	  <name>Greater Manchester Mental Health NHS Foundation Trust</name>
	  <address>Prestwich Hospital
Bury New Road
Prestwich</address>
	  <city>Manchester</city>
	  <state/>
	  <country>England</country>
	  <zip>M25 3BL</zip>
	  <rtsId>RXV@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1.  Aged 18 or older  
2. Resident of a temporary accommodation
3. One or more of the below:
3.1. Mental health problem  
3.2. Substance (includes alcohol) use  
3.3. History of criminal justice encounter 
3.4. Equal to or longer than 6 months in one stay or repeat stay in temporary accommodations</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="125.0">125 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>426</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>Residents lacking mental capacity to consent</exclusion>
      <recruitmentStart>2027-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Homelessness, mental health, substance use disorders, multiple complex needs</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>REACH will be delivered by a care team consisting of a mental health practitioner who will be recruited from a local NHS Trust alongside a named care navigator from a local voluntary, charity, social enterprise (VCSE)/NHS Trust. The intervention team will use a strengths-based approach to engage with participants and agree shared goals. The care team will look after approximately 18-22 participants, meeting them weekly/as required. The King's Clinical Trials Unit (KCTU) will provide a bespoke web-based randomisation system to allocate participants to the intervention in addition to usual care or usual care alone. 

The intervention will be highly structured. In addition to Usual care, REACH will include:
1. Holistic health and care needs assessment (procedures tested in our pilot study); mental health (anxiety, depression, psychosis, PTSD assessment); substance use disorders, physical health (e.g. blood pressure, BMI, random glucose, referral for a 12-point ECG if risk factors identified, blood borne viruses, dyspnoea assessment; skin integrity/pressure ulcers, foot assessment). 
2. Facilitating access to national health screening programmes (e.g. &gt; 40 health checks), flu/COVID-19 vaccination, Hepatitis B, shingles (if eligible), pharmacy smoking cessation. 
3. Intervention staff will offer immediate treatment (within areas of expertise) or arrange referrals and accompany participants to appointments for the provision of evidence-based therapies (e.g. CBT), support medication optimisation and adherence, expedited (often the same day) referral to local Drug &amp; Alcohol treatment providers, facilitating care pathways for traumatic brain injuries.
4. Social-needs assessment and support (housing, welfare benefits assessment, bank account, criminal justice, clothing, access to nutritious meals).
5. Harm reduction (e.g. naloxone training and supply, support for safe substance consumption including needle exchange and foil provision, sexual health advice, condom provision and referral).
6. Attendance at the multi-agency weekly meeting and formulation of multiagency care plan with action points for each agency.
7. Social prescribing, facilitation of access to free bus passes or provision (up to £150 per person for participants non-eligible through other means); liaison with local organisations for available opportunities to address isolation/boredom, facilitate participation in sustainable employment training skills that are available locally (e.g. IT skills), green prescribing initiatives (gardening, arts/crafts) and promote wellbeing.
8. Step-up accommodation/street outreach: intervention will continue if participant transitions to another setting.
9. Support for family reconnections if desirable by study participants.

Initial consultations will be held in temporary accommodation consultation/safe areas. Care team will also utilise nearby community centres, local GP practices, VCSE hubs and soup kitchens as agreeable by the participants and venue providers. Uptake of REACH will be maximised, and dropout minimised, through proactive follow up, door knocking and assertive outreach where participants move on to other accommodation providers or streets. Intervention will last for up to 12 months to allow sufficient time for the REACH team to develop trust/rapport with participants, provide treatment and sustain recovery. Throughout the intervention the patient will continue to engage with mainstream care. When the intervention period finishes, the participant will return to receiving usual care alone.

Usual care: Participants will receive care as usual from the temporary accommodation staff and any existing support from external providers. In addition, a leaflet will be provided by the recruiting researcher describing health and care support available for people experiencing homelessness (PEH) in the area.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>c279992d-3f54-4e95-a73a-4d05a58673be</funderId>
      <contactId>021c2c8c-9ffc-4e66-9879-6c96117c1e67</contactId>
      <contactId>722ea6c6-43af-49e0-a698-e345ea7b1cfd</contactId>
      <sponsorId>c2ff360e-a426-4cd9-8a6a-677052a2f676</sponsorId>
      <sponsorId>c3aab693-8709-4976-8449-5dd9786a97eb</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="021c2c8c-9ffc-4e66-9879-6c96117c1e67">
    <title>Prof</title>
    <forename>Vibhu</forename>
    <surname>Paudyal</surname>
    <orcid>https://orcid.org/0009-0001-3887-8893</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>King's College London</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SE1 8WA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7836 5454</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vibhu.paudyal@kcl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="722ea6c6-43af-49e0-a698-e345ea7b1cfd">
    <title>Ms</title>
    <forename>Lena</forename>
    <surname>Johansson</surname>
    <orcid>https://orcid.org/0000-0002-4473-1134</orcid>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>King's Clinical Trials Unit, 16 De Crespigny Park</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SE5 8AF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">44 (0)20 7848 0532</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">reachtrial@kcl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="c2ff360e-a426-4cd9-8a6a-677052a2f676">
    <organisation>King's College London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/0220mzb33</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <sponsor id="c3aab693-8709-4976-8449-5dd9786a97eb">
    <organisation>South London and Maudsley NHS Foundation Trust</organisation>
    <sponsorType/>
    <rorId>https://ror.org/015803449</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="c279992d-3f54-4e95-a73a-4d05a58673be">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-10-27T09:22:43.15284081Z" version="10" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN14389109" publicIdentifierDateAssigned="2026-10-27T16:56:16.156785Z">
    <isrctn dateAssigned="2026-10-27T16:56:16.156785Z">14389109</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>Supporting the mental health of women affected by floods in rural Pakistan: a pilot study</title>
      <scientificTitle>Psychosocial support for women in post-flood settings: a mixed-methods pilot of community-based psychological first aid and problem management plus in rural Pakistan</scientificTitle>
      <acronym/>
      <studyHypothesis>The study objectives are to explore preliminary signals of change in:
1. The knowledge, skills, and mental health awareness and sensitivity of female health workers following capacity-building training in PFA and PM+ delivery.
2. Mental health outcomes (depression, anxiety, PTSD, and resilience) of flood-affected women following a tailored PFA and PM+ intervention delivered through female health workers.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Floods in Pakistan cause not only physical harm but also significant psychological distress, particularly among women. This study aimed to pilot a low-cost, tailored intervention combining WHO-endorsed Psychological First Aid (PFA) and Problem Management Plus (PM+) in post-flood affected communities in Thatta, Sindh province, and assess feasibility through changes in health worker training outcomes and mental health outcomes of flood-affected women, alongside implementation experiences, perceived outcomes, and barriers and facilitators to delivery. 

Who can participate?
Female health workers aged between 18-65 years, who can speak and understand Sindhi and Urdu languages, have at least completed Matriculation, and are actively working with flood-affected people in interior Sindh. Also, flood-affected women (known as Marvi Workers) would receive the intervention via convenience sampling by their local female health workers as part of their ongoing in-person visits. The inclusion criteria is female participants aged between 18-65 years, who could speak and understand Sindhi or Urdu, had directly or indirectly been affected by floods, and get a score of 20 or higher on the Kessler Psychological Distress Scale (K-10).

What does the study involve?
The study involve two phases. Phase 1 is a scoping visit to adapt the PFA and PM+ manuals, capacity-building training, and pre- and post-assessments of female health workers. Phase II involve recruitment of flood-affected women (Marvi Workers) with psychological distress and delivered four monthly tailored PFA and PM+ sessions. Changes in depression, anxiety, PTSD, and resilience scores were assessed. Focus group discussions with female health workers and in-depth interviews with Marvi Workers captured qualitative insights. 

What are the possible benefits and risks of participating?
Potential benefits included improved mental wellbeing and coping skills. Risks were minimal and participants could withdraw at any time and were referred for further professional support if needed.

Where is the study run from?
The study was conducted in Thatta district, Sindh Province, Pakistan, and was coordinated through Interactive Research and Development (IRD Global) (Pakistan)

When is the study starting and how long is it expected to run for?
July 2023 to October 2023

Who is funding the study?
This study was funded by the National Institute for Health and Care Research (NIHR) (UK) through its Research and Innovation for Global Health Transformation (RIGHT) programme (grant number NIHR200824), using UK international development funding from the UK Government to support global health research. The study was supported through the PIECEs Small Scale Research Grant, administered by Queen Mary University of London (UK).

Who is the main contact?
Mehwish Dawood, dawoodm@oregonstate.edu</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="c07b8c82-1383-49f2-ad69-8536a3ae0d85">
	  <variable>Depression</variable>
	  <method>the Patient Health Questionnaire-9 (PHQ-9)</method>
	  <timepoints>baseline (before the intervention started) pre-intervention assessment and endline (immediately after the conclusion of  final fourth session)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="02b48500-c81d-442f-9fed-cb4ece8ca218">
	  <variable>Anxiety</variable>
	  <method>the Generalized Anxiety Disorder Questionnaire (GAD-7)</method>
	  <timepoints>baseline (before the intervention started) pre-intervention assessment and endline (immediately after the conclusion of  final fourth session)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="d4413a8b-f4c4-4117-aa94-587900966a55">
	  <variable>PTSD</variable>
	  <method>the PTSD Checklist for DSM-5 (PCL-5)</method>
	  <timepoints>baseline (before the intervention started) pre-intervention assessment and endline (immediately after the conclusion of  final fourth session)</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c8f945fa-8061-481d-b479-4b94e44bcadf">
	  <variable>Resilience</variable>
	  <method>the Resilience Scale (RS-14)</method>
	  <timepoints>baseline (before the intervention started) pre-intervention assessment and endline (immediately after the conclusion of  final fourth session)</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="e6f0499f-ecdc-4396-9301-7cd9bfe970d1" approvalStatus="approved" statusDate="2023-04-11T00:00:00.000Z">
	  <committeeName>Institutional Review Board of Interactive Research &amp; Development (IRD) Global in Pakistan</committeeName>
	  <contactDetails>
	    <address>4th Floor, Woodcraft Building, Plot 3 &amp; 3-A, Sector 47, Korangi Creek Road</address>
	    <city>Karachi</city>
	    <state/>
	    <country>Pakistan</country>
	    <zip>75190</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>IRD_IRB_2023_02_002</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14389109</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers/>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>N/A: single arm study</allocation>
	<masking>Open (masking not used)</masking>
	<control>Uncontrolled</control>
	<assignment>Single</assignment>
	<purposes>
	  <purpose>Health services research</purpose>
	  <purpose>Prevention</purpose>
	  <purpose>Supportive care</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2023-10-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Pakistan</country>
      </recruitmentCountries>
      <trialCentres/>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>Marvi Workers (MWs):
1. Female participants aged between 18-65 years
2. Speak and understand Sindhi or Urdu
3. Directly or indirectly affected by flood
4. Score of 20 or higher on the Kessler Psychological Distress Scale (K-10)

Lady Health Visitors (LHVs):
1. Aged between 18-65 years
2. Speak and understand Sindhi and Urdu languages
3. Have at least completed Matriculation
4. Actively working with flood-affected people in interior Sindh</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="65.0">65 Years</upperAgeLimit>
      <gender>Female</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment>40</totalFinalEnrolment>
      <exclusion>1. Individuals with severe mental illness or cognitive impairment
2. Unable to provide informed consent</exclusion>
      <recruitmentStart>2023-07-04T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2023-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Psychological distress, depression, and anxiety in flood-affected women in Sindh Province, Pakistan</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants are flood-affected women experiencing psychological distress residing in Thatta district, Sindh Province, Pakistan. This is a single-arm pilot study with no control group. 

Participants receive a culturally adapted combined intervention comprising Psychological First Aid (PFA) and Problem Management Plus (PM+), delivered by trained Lady Health Visitors (LHVs) from the community. The LHVs are recruited via convenience sampling from HANDS to receive capacity-building training on PFA and PM+. And the flood-affected women (Marvi Workers) are recruited to receive the intervention via convenience sampling by their local LHVs as part of their ongoing in-person visits.

The tailored intervention combining the PFA and PM+ sessions includes: PFA component is delivered using the Look-Listen-Link framework to provide immediate psychosocial support and connect women to available resources.

The PM+ component covers evidence-based strategies including stress management skills, and problem-solving techniques, behavioral activation through task-oriented activities and explore avenues for strengthening social support and developing new skills. The adapted intervention consists of four monthly sessions, each lasting 45 to 60 minutes, and session content from PM+ Session 5 (staying well and looking forward) is integrated into the final session.

Participants complete standardized quantitative assessments at baseline and endline.  A subset of participants also takes part in individual in-depth interviews (IDIs) and focus group discussions (FGDs) to explore their experiences of the intervention. All sessions and qualitative data collection are conducted in in-person in Sindhi and Urdu by female researchers and LHVs.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>1e0dffd6-aeab-4337-a899-013e637c9bec</funderId>
      <funderId>9c07b651-c70d-4f15-b7ab-f0ea15eb3ffc</funderId>
      <contactId>3ea42db1-88f9-444f-8171-c6513c10e35d</contactId>
      <contactId>217d37f1-6316-4571-9854-59add5fb3913</contactId>
      <sponsorId>b1595245-f2c7-4d94-892c-a30bcbb237e0</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="3ea42db1-88f9-444f-8171-c6513c10e35d">
    <title>Ms</title>
    <forename>Mehwish</forename>
    <surname>Dawood</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Oregon State University, 1500 SW Jefferson Way</address>
      <city>Corvallis</city>
      <state/>
      <country>United States of America</country>
      <zip>97331</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">N/A</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dawoodm@oregonstate.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="217d37f1-6316-4571-9854-59add5fb3913">
    <title>Ms</title>
    <forename>Aatika</forename>
    <surname>Ahmed</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>New York University, 50 W 4th St</address>
      <city>New York</city>
      <state/>
      <country>United States of America</country>
      <zip>10012</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">N/A</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ahmed.aatika8@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="b1595245-f2c7-4d94-892c-a30bcbb237e0">
    <organisation>Interactive Research and Development</organisation>
    <sponsorType/>
    <rorId>https://ror.org/04mccvy52</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="1e0dffd6-aeab-4337-a899-013e637c9bec">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
  <funder id="9c07b651-c70d-4f15-b7ab-f0ea15eb3ffc">
    <name>Queen Mary University of London</name>
    <fundRef>http://dx.doi.org/10.13039/100009148</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-10-27T08:36:54.035026792Z" version="14" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN77931273" publicIdentifierDateAssigned="2026-10-27T08:36:54.236791Z">
    <isrctn dateAssigned="2026-10-27T08:36:54.236791Z">77931273</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A trial aiming to determine whether giving thiamine (a vitamin) can help prevent or treat delirium in patients who are admitted to intensive care</title>
      <scientificTitle>A double-blind randomised clinical trial of supplementary intravenous thiamine versus placebo in the treatment and prevention of delirium in the intensive care unit</scientificTitle>
      <acronym>DELTA-ICU</acronym>
      <studyHypothesis>The principal research question aims to find out the effect of thiamine to prevent or shorten the duration of delirium and therefore improve outcomes for critically ill adults who are receiving organ support (for example to help their breathing, heart or kidneys) on a intensive care unit. This is defined by the outcome of days alive and free from delirium and coma up to 14 days (this encompasses both survival and whether the patient is assessed to have delirium).

The secondary objectives are to investigate the effect of the intervention on other important patient and healthcare centred
outcomes.</studyHypothesis>
      <plainEnglishSummary>Background and study aims 
Over 50% of patients who are admitted to the Intensive Care Unit (ICU) will suffer from a condition called delirium (a sudden state of confusion and altered awareness) during their stay. This causes problems with attention, thinking, and memory, and can include frightening hallucinations (seeing or hearing things that only exist in the mind) or delusions.  Delirium is associated with negative outcomes that are important to patients, including longer time spent in the ICU/hospital, increased chance of dying, loss of independent function, and long-term emotional distress.
Researchers believe delirium is caused by brain cells not being able to produce energy properly. Vitamin B1, known as thiamine, is a very safe and cheap medication. We believe giving thiamine to ICU patients could reduce delirium by helping brain cells produce energy, but there is little clinical evidence to support this. The study aims to determine whether thiamine can reduce delirium in ICU patients and improve their recovery. 

Who can participate? 
Patients aged 18 years and over receiving either invasive mechanical ventilation or two or more organ support (defined as respiratory [non-invasive ventilation or high flow nasal oxygen], cardiovascular [new requirement for vasopressor treatment] or renal support [new acute renal replacement therapy]) within 48 hours of ICU admission

What does the study involve? 
This study will compare intravenous thiamine with a placebo (a treatment with no active ingredient). Participants will be randomly allocated to receive either thiamine or placebo, and neither the participants nor the healthcare professionals caring for them will know which treatment has been given. This approach helps ensure that the results are reliable and unbiased. Researchers will assess a range of important health outcomes, including recovery from critical illness, length of stay in hospital, quality of life after discharge, and the safety of the treatment. In addition, blood and urine samples will be analysed to help understand how thiamine may affect the body and brain during critical illness. 

What are the possible benefits and risks of participating? 
The findings from DELTA-ICU may help improve the care of future ICU patients.
Potential risks and benefits of taking part in the trial will be fully detailed in the Patient and Legal Representative Information Sheets.
Thiamine (vitamin B1) is a safe drug, with minimal side effects. Patients in both groups will be closely monitored for serious adverse events that may be related to the trial treatments. Data on serious adverse events will be collected on all study participants. Safety will be monitored by the independent Data Monitoring and Ethics Committee (at a schedule deemed appropriate by the Committee) who will recommend the continuation (or not) of the trial to the majority-independent Trial Steering Committee.
The trial involves biological samples being obtained from all participants. A blood and urine sample will be obtained at baseline, during the intervention and at Day 14 (or discharge from the intensive care unit, whichever is sooner). Most participants due to the critical nature of their illness will have an arterial or central line inserted for their care and a urine drain. Therefore, blood samples will be obtained from inserted lines causing no additional burden to the participant and where possible these will be obtained alongside clinical bloods by trained members of staff.  Urine samples will be obtained from the urine drain, or if no urine drain is in place and the participant is able, they will provide their own sample in a urine pot.
As the trial will use identifiable and health data, there is a small risk that data could be lost or breached. Robust measures will be in place to prevent this from occurring – e.g. through the implementation of regular data backup arrangements and data disaster recovery procedures. All trial data will be entered onto a database (Open Clinica) by the recruiting NHS hospital. Open Clinica is secure and validated for use in clinical trials. Access will be closely controlled by ICNARC Clinical Trials Unit. Identifiable data will only be collected where essential. Participants will be allocated a unique Trial Number to minimise processing of identifiable data. We will use data linkage for routinely collected patient data and additional in-hospital data collection into a case report form. 
One potential perceived burden to patients taking part in the trial could be the completion of follow-up questionnaires at 90 days. The questionnaires will be conducted over the phone and should take no longer than 15 minutes to complete. All information on the follow up questionnaires will be provided on the Patient / Legal Representative Information Sheet participants will be presented with this as an option to consent (or not) for this on the consent form. Our previous studies have achieved response rates ranging 75-80% of critical care survivors.

Where is the study run from? 
Intensive Care National Audit &amp; Research Centre (UK)

When is the study starting and how long is it expected to run for?
September 2026 to January 2029

Who is funding the study? 
Efficacy and Mechanism Evaluation Programme (UK)

Who is the main contact?
1. Dr Catherine McKenzie, c.a.mckenzie@soton.ac.uk
2. DELTA – ICU trial team, DELTA-ICU@icnarc.org</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>The number of days a patient is alive and free of delirium and coma up to day 14 following randomisation (with day 1 being the day of randomisation):
 1. Days alive will be measured by reviewing patient records by local site teams.
2. Delirium incidence will be collected using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU), this will be conducted and collected twice daily, one positive test in 24 hours will be considered a day in delirium. If both CAM-ICU screens are negative this will be considered a delirium-free day.
3. Coma data will be assessed via the routinely documented Richmond Agitation and Sedation Score (RASS). If the RASS is -3 or lower at time of both delirium screens (CAM-ICU) and we are therefore unable to assess delirium; this will be considered a day in coma.</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Days alive and free of advanced respiratory support (as per Case Mix Programme [CMP] definitions) up to day 30, measured by reviewing local patient records
2. Mortality at ICU and hospital discharge, 30 and 90 days, measured by reviewing local patient records
3. ICU and hospital length of stay, measured by reviewing local patient records
4. Discharge to home or long-term care facility, measured by reviewing local patient records
5. Health-related quality of life measured using the EQ-5D-5L at 90 days
6. Cognitive function measured using the Telephone Montreal Cognitive Assessment (T-MOCA) questionnaire at 90 days</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="549d1921-a0fd-49df-b1b6-aa63788dc111" approvalStatus="notYetSubmitted">
	  <committeeName/>
	  <contactDetails>
	    <address/>
	    <city/>
	    <state/>
	    <country/>
	    <zip/>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference/>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77931273</doi>
      <eudraCTNumber/>
      <irasNumber>1008065</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CRI0480</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="73a5d678-d8f5-4e2b-b577-cafd45926ac5" numberType="iras" canonicalSecondaryNumber="IRAS1008065">1008065</secondaryNumber>
	<secondaryNumber id="d1bfb36d-5785-453f-83a0-9f253aa659b0" numberType="Sponsor's protocol code number">CRI0480</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Placebo</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Prevention</purpose>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Efficacy</trialType>
	<trialType>Treatment</trialType>
	<trialType>Other</trialType>
      </trialTypes>
      <overallEndDate>2029-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4dfe35a6-5257-4598-9a99-d2a793001248">
	  <name>-</name>
	  <address>-</address>
	  <city>-</city>
	  <state/>
	  <country>England</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Adult (aged ≥18 years)
2. Receiving either:
2.1. Invasive mechanical ventilation
2.2. Two or more organ support (defined as respiratory [non-invasive ventilation or high flow nasal oxygen], cardiovascular [new requirement for vasopressor treatment] or renal support [new acute renal replacement therapy])
3. Within 48 hours of ICU admission</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>520</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Taking prescribed thiamine at the time of ICU admission, by any route, or a clinical indication for supplementary intravenous thiamine, for example: 
1.1. Documented or suspected alcohol dependence - with high risk of Wernicke’s-Korsakoff Syndrome or alcohol withdrawal syndrome on ICU admission
1.2.  Severe or moderate malnutrition on ICU admission with high risk of refeeding syndrome 
2. Known allergy to thiamine
3. Expected to be discharged from ICU within 48 hours
4. Death perceived as imminent or for end of life care only 
5. Neurological injury that prevents assessment of delirium, e.g., traumatic brain injury, intracranial haemorrhage or ischaemic brain injury from stroke or hypoperfusion
6. Pre-existing neurocognitive disorders that prevent the assessment of delirium, e.g., severe dementia, severe learning difficulties
7. Confirmed pregnancy or breastfeeding</exclusion>
      <recruitmentStart>2026-09-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Delirium</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Following assessment of eligibility patients will be randomised to the trial using a central web-based randomisation system. Patients will be allocated 1:1 to receive either blinded intravenous thiamine or placebo (0.9% sodium chloride) with the output from the randomisation website being an instruction to the site team to prescribe a specifically numbered kit (which will contain 24 ampoules of either thiamine or placebo).

One ampoule of the IMP (thiamine [250 mg] or placebo [0.9% sodium chloride]) should be prepared for administration in a volume of 0.9% sodium chloride, between 50 to 100 ml, depending on site preparation and administration of medication in critical care. In a clinical scenario where 0.9% sodium chloride is to be avoided, then the IMP may be prepared in glucose 5%. The prepared blinded IMP will be given intravenously over 30 minutes, initially 8 hourly for 5 days followed by daily up to a total of 14 days or until ICU discharge, whichever comes first.

The participant will be followed up with survival status collected at day 14 (for contribution to the primary outcome) and at the day 90 timepoint. This will be obtained by review of the patient's medical records by the local research team. If appropriate, participants will be followed up using the Telephone Montreal Cognitive Assessment (T-MOCA) and EQ-5D-5L questionnaire at 90 days post-randomisation.</description>
	<interventionType>Drug</interventionType>
	<phase>Phase II</phase>
	<drugNames>Thiamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study will be available upon request via https://www.icnarc.org/data-services/access-our-data/</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Available on request</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>5f815d5d-e4dc-4dda-88ce-8da6a930f2a4</funderId>
      <contactId>ae0db1a0-b1a2-4597-9871-7851bb8af8e1</contactId>
      <contactId>84e78384-639d-49f3-9378-f33708b861e0</contactId>
      <sponsorId>975918f3-4bf2-440d-a0b2-25e217159b2d</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="ae0db1a0-b1a2-4597-9871-7851bb8af8e1">
    <title>None</title>
    <forename>DELTA – ICU</forename>
    <surname>Trial Team</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Napier House, 24 High Holborn</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>WC1V 6AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)207831 6878</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">DELTA-ICU@icnarc.org</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="84e78384-639d-49f3-9378-f33708b861e0">
    <title>Dr</title>
    <forename>Catherine</forename>
    <surname>McKenzie</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Road</address>
      <city>Southampton</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SO17 1BJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)23 8022 2777</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.a.mckenzie@soton.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="975918f3-4bf2-440d-a0b2-25e217159b2d">
    <organisation>Intensive Care National Audit &amp; Research Centre</organisation>
    <sponsorType/>
    <rorId>https://ror.org/057b2ek35</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="5f815d5d-e4dc-4dda-88ce-8da6a930f2a4">
    <name>Efficacy and Mechanism Evaluation Programme</name>
    <fundRef>http://dx.doi.org/10.13039/501100001922</fundRef>
  </funder>
</fullTrial></allTrials>